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To my family  
  
 ABSTRACT  
Background: End-stage renal disease (ESRD) and preeclampsia (PE) are associated 
with high risk of cardiovascular events and characterized by endothelial dysfunction. 
Resistance arteries are actively involved in the control of blood pressure and blood 
flow to the target organs. The expansion of the current knowledge specific to the 
structure and function of resistance arteries in subjects with increased risk of 
cardiovascular events is of importance for clinical practice.  
Overall aim: To investigate structure and function of resistance arteries isolated from 
ESRD patients, women with PE and women at reproductive age with a history of 
early-onset PE.  
Results: 
Study I. Reduced flow- and acetylcholine-induced dilatations, but preserve response 
to NO donor were found in arteries from the ESRD group vs. controls. Deficiency of 
NO was evident in flow-induced response. Distensibility was reduced in the ESRD 
group, but vascular structure, myogenic tone and sensitivity to vasoconstrictors 
remained unchanged. Increased ADMA levels and enhanced expression of 
nitrotyrosine were found in arteries from the ESRD group. Exclusion of ESRD 
patients with diabetes and/or cardiovascular diseases from analyses had no influence 
on the main findings. 
Studies II-III. Dilatation to bradykinin (BK) was reduced in myometrial but not in 
subcutaneous arteries from pregnant women with PE vs. controls. In PE, 
endothelium-derived hyperpolarizing factor (EDHF)-type responses were impaired in 
both types of arteries. The contribution of myoendothelial gap junctions (MEGJs), 
implicated as a common pathway of EDHF-type responses in arteries from normal 
pregnant women, became reduced in subcutaneous and particularly diminutive in 
myometrial arteries from women with PE. The reduced contribution of MEGJs in PE 
was partly compensated by H2O2 alone (myometrial) or in combination with 
cytochrome P450 metabolites of arachidonic acid (subcutaneous arteries). 
Study IV. Reduced dilatation to flow due to the lack of NO contribution, increased 
myogenic tone, higher sensitivity to norepinephrine and reduced distensibility were 
observed in arteries from women with a history of early-onset PE vs. controls. 
Responses to BK and NO donor were similar between the groups. Basal tone and 
arterial structure were preserved in women with a history of PE. 
Conclusions: Uraemia primarily targets endothelial function and elastic properties of 
resistance arteries. The lack of NO contribution to flow-induced dilatation together 
with enhanced circulating levels of ADMA and enhanced nitrotyrosine staining in the 
vascular wall support the critical role of NO deficiency in resistance arteries from 
ESRD patients.  
In PE endothelial function of myometrial arteries is primarily targeted. This could 
significantly contribute to the impaired uteroplacental blood flow. EDHF-type 
responses through MEGJs are the major compromised pathway of endothelium-
dependent dilatation in both myometrial and subcutaneous arteries in PE. The 
attenuated role of MEGJs in PE is partly compensated through the contribution of H2O2 or other endothelium-derived factors. 
Functional alterations in subcutaneous arteries from women with a history of early-
onset PE might create prerequisites for the increased peripheral resistance with 
following impact on the long-term cardiovascular health.  
Key words: Resistance arteries, preeclampsia, end-stage renal disease, endothelium, 
nitric oxide, endothelium-derived hyperpolarizing factor, flow-induced dilatation, 
myogenic tone, distensibility. 
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1 INTRODUCTION 
 
Small arteries with internal diameter within range from 0.1 to 0.3 mm and arterioles 
(diameter of <0.1mm) are the major site of resistance to blood flow and as such they 
contribute considerably to the control of peripheral resistance, blood pressure and blood 
flow. The disturbances in these parameters of cardiovascular function represent a 
background for the development of a number of cardiovascular diseases (CVD). Thus, 
the elucidation of functional and morphological abnormalities that take place at the 
level of resistance circulation may provide means for primary and secondary prevention 
of cardiovascular complications in the wide range of different patients.  
 
A tremendous importance of small arteries in the maintenance of cardiovascular 
function explains a considerable interest of biomedical research to the structural and 
functional characteristics of these arteries in health and disease. Moreover, a previous 
approach of extrapolation of the knowledge obtained on large arteries to the level of 
microcirculation could not be considered as appropriate. Indeed, current data clearly 
indicates on morphological and functional differences between small and large arteries. 
For example, several mechanisms involved in the control of vasomotor tone at the level 
of small arteries (e.g. myogenic autoregulation, flow-induced and metabolic dilatation, 
contribution of endothelium-derived hyperpolarizing factor (EDHF) and gap junctions 
to the endothelium-dependent function, sympathetic constriction, etc.) are very poor, if 
at all, represented at the level of conduit arteries. Therefore, the extension of the 
knowledge peculiar to morphology and function of small arteries in health and disease 
is of importance for clinical practice.  
 
The general aim of this thesis is to expand the current knowledge about the structure 
and vasomotor tone control of small arteries in patients with end-stage renal disease 
(ESRD), pregnancy-specific disorder preeclampsia (PE) and in women at reproductive 
age with a history of PE. 
 
1.1 SMALL ARTERY STRUCTURE 
 
As in any other blood vessels, the vascular wall of small arteries consists of three layers 
(Mulvany, 1990). Each layer has certain influence on the vasomotor tone.  Tunica 
intima is the inner layer, which composed of endothelial cells (ECs) oriented 
longitudinally to sense shear stress forces created by blood flow. Despite the 
endothelium has the only one layer of ECs, its role in the control of vasomotor tone 
through the release of vasoactive substances is of vast importance. This will be 
described below in the details.  
 
The endothelium is separated by the internal elastic lamina (IEL) from the underlying 
layer i.e. tunica media. IEL of small arteries is fenestrated and protrusions from ECs 
and smooth muscle cells (SMCs) can reach each other  via formation of myoendothelial 
gap junctions (MEGJs), which play an important role in numerous aspects of vascular 
function and pathology (Dhein, 2004).  
 
The thickest layer of the vascular wall, tunica media, containing SMCs oriented 
perpendicularly to the lumen of the artery and therefore can develop circumferential 
force. External elastic lamina separates tunica media and adventitia. The outer 
adventitial layer includes perivascular sympathetic nerves, extracellular matrix and 
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fibroblasts. Recent data indicate that adventitia contains proteins that could play an 
important role in vascular smooth muscle function as well (Auger et al., 2007).  
 
The structure of small arteries is not static and under influence of the hemodynamic 
conditions. Changes in the wall/lumen ratio and cross-section area reflect structural 
alterations and indicate a remodelling process. 
 
1.2 THE ROLE OF SMALL ARTERIES  
 
In contrast to the conduit arteries, the vascular wall of small arteries contains more 
smooth muscles than elastic materials reflecting the specificity of their functional 
properties. Small arteries can easily adapt their diameter by constriction or dilatation in 
accordance with metabolic needs of the supplied tissue or organs.  
 
In accordance with Poiseuille's law, the resistance can be expressed as: 
R=8ηL/πr4, 
where η is viscosity of fluid, L – length, and r – radius of the vessel. Because of the 
fourth power of the radius, small changes in vascular diameter will have significant 
effects on resistance and blood flow. This in turn will directly influence blood pressure, 
since   
P=R×Q, 
where P is pressure, R – resistance, and Q – blood flow. 
 
Hereby, small arteries, because of their intrinsic ability to change the diameter, play an 
important role in the regulation of blood flow to the target organs and have a pivotal 
role in the control of systemic blood pressure (Christensen and Mulvany, 2001).  
 
1.3 THE VASCULAR TONE REGULATION  
 
The diameter of small arteries is under central (neuro-humoral) and local regulations. 
The relative contribution of each might be different depending from the vascular beds 
and physiological conditions. For example, the hormonal regulation has minor 
influence on the arterial diameter in the healthy individuals under normal conditions, 
but it becomes predominant under physical activity or in some pathophysiological 
situations.  
 
Mechanisms of local vascular control involve myogenic activity and local humoral 
factors. Myogenic regulation is based on an intrinsic mode of control of vascular 
reactivity i.e. without direct effects of nerves and hormones. Stretch, mediated by 
perfusion pressure, triggers the mechanism of myogenic constriction. Humoral factors, 
which include metabolites, hormones, and mediators, affect significantly vascular tone. 
For example, any chemical alterations in the interstitial fluid mediated by high 
metabolic rate (e.g., the low PO2, pH, and adenosine triphosphate (ATP) levels as well 
as the high levels of PCO2, adenosine, and K+) will challenge relaxation and increase 
blood flow.  
 
1.3.1 Endothelium-dependent regulation of the vasomotor tone 
 
Strategically located between the blood and vascular wall, the endothelium is a major 
player in the control of blood fluidity, platelet aggregation, permeability, and vascular 
tone regulation. Furthermore, the endothelium is the largest endocrine organ in the 
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body and it has an important role in the regulation of inflammation, immunological 
responses, and angiogenesis.  
 
ECs control the tone of the underlying vascular SMCs by releasing relaxing and 
contracting factors and by interacting directly with the vascular SMCs through the 
MEGJs (Feletou M, 2008). Vasodilator capacity of the endothelium is accounted by its 
ability to release primarily three powerful factors, namely nitric oxide (NO), EDHF and 
prostacyclin (PGI2), whereas endothelin-1 (ET-1) and thromboxane A2 (TX A2)  are the 
main endothelium-derived vasoconstrictors. 
 
NO, a short-lived free radical gas with a high biological activity, is produced by L-
arginine-endothelial nitric oxide synthase (eNOS) system in the presence of molecular 
oxygen (Palmer et al., 1987). The eNOS is expressed constantly and associated with 
caveolin-1, which inhibits eNOS activity (Dudzinski and Michel, 2007). eNOS-
calcium/calmodulin interaction is required for its activation. Heat-shock protein 90 
(HSP-90) acts as a chaperone and increases eNOS activity by enhancing the affinity of 
eNOS for calmodulin and facilitates the interaction with Akt kinase (Garcia-Cardena et 
al., 1998). Several co-factors are required including nicotinamide adenine dinucleotide 
phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide 
(FMN) and tetrahydrobiopterin (BH4) in order to catalyze this reaction (Forstermann et 
al., 1994). NO activates soluble guanylyl cyclase (sGC) of SMCs, with following 
increase in intracellular cyclic guanosine monophosphate (cGMP) and activation of 
protein kinase G leading to reduced intracellular calcium and relaxation (Hobbs and 
Ignarro, 1996). 
 
PGI2 – a cyclooxygenase (COX)-dependent metabolite of arachidonic acid (AA) 
(Dusting GJ, 1977). PGI2 elicits relaxation through binding to specific cell-surface PGI2 
receptors resulting in G-protein mediated activation of adenylate cyclase and formation 
of cAMP (cyclic adenosine monophosphate). This phosphorylates protein kinase A and 
results in the reduction of calcium in SMCs and vasodilatation (Mitchell et al., 2008). 
 
Hyperpolarization is a mechanism behind of the third pathway of endothelium-
dependent relaxation, which is known as EDHF type response. This pathway of 
endothelial control of vascular tone is considered as a signal generated and released by 
hyperpolarized ECs. Endothelium-derived hyperpolorizing signal can activate K+ 
channels and causes hyperpolarization of the underlying SMCs. In turn, 
hyperpolarization of vascular SMCs elicits the closure of voltage-gated calcium 
channels (Edwards et al., 2010) followed by decrease in intracellular calcium 
concentration and subsequent relaxation. Currently, there are numerous evidences for 
heterogeneous nature of EDHF. Structurally very different factors including 
cytochrome P450 (CYP450) products of AA (Rubanyi GM, 1987; Campbell and 
Fleming, 2010), hydrogen peroxide (H2O2) (Shimokawa and Morikawa, 2005), C-type 
natriuretic peptide (Chauhan et al., 2003) and  potassium ions released by 
hyperpolarized ECs (Edwards et al., 1998) have been introduced as potential candidates 
for EDHF. Furthermore, ECs hyperpolarisation could be also transmitted to SMCs 
through   MEGJs (Chaytor et al., 1998) that are clusters of intercellular channels 
formed by membrane-located connexin (Cx) proteins. There is a number of excellent 
reviews summarizing current data about potential candidates for the role of EDHF 
(McGuire JJ, 2001; Félétou and Vanhoutte, 2006; Luksha et al., 2009; Edwards and 
Félétou et al., 2010). 
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Hereby, the endothelium is actively involved in the regulation of vascular tone via 
release of vasoactive compounds.  Some of them are released continuously, whereas 
others after stimulation with either pharmacological (endothelium-dependent agonists 
i.e. acetylcholine (ACh), bradykinin (BK), substance P) or physical/mechanical (flow-
induced shear stress) stimuli. Physiologically, ECs maintain a relaxed vascular tone and 
low levels of oxidative stress. Therefore, healthy endothelium, as defined in terms of 
the vasodilator response to endothelium-dependent agonists and blood flow, is an 
important indicator of cardiovascular health. The endothelium is not only largest 
endocrine/paracrine organ in the human body, but also the target organ for many active 
substances. Endothelial dysfunction is defined as reversible alterations of endothelial 
function resulting from the misbalance between endothelium-derived vasodilators and 
vasoconstrictors. It is now widely appreciated that endothelial dysfunction is the initial 
pathophysiological step in progression of vascular damage that leads to CVD (Katakam 
et al., 1998; Prasad et al., 2003; Szűcs et al., 2007). 
 
1.3.2 Hemodynamic forces in the control of vascular tone 
 
Mechanical forces associated with blood flow play an important role in the acute 
control of vascular tone. Forces acting on vascular wall due to blood flow can be 
divided into two principal vectors. One is parallel to the wall to create a frictional force, 
shear stress, at the surface of the endothelium, and the other acts perpendicular to the 
wall and represents blood pressure (Davies, 1995). Whereas transmural pressure is 
transferred to all vascular wall layers (intima, media and adventitia), shear stress is 
applied only on the inner EC layer.  
 
1.3.2.1 Flow-induced responses  
 
The physiological relevance of flow-induced relaxation firstly refers to the regulation 
of arterial diameter. In addition, physiological shear stress, induced by laminar blood 
flow, may act as an atheroprotective factor (Davies, 1995) and promote 
anticoagulation through the inhibition of platelet aggregation (Diamond et al., 1989), 
leukocyte adhesion and SMCs proliferation (Berk et al., 2001). 
 
Significance of blood flow, as an important hemodynamic force in the control of the 
vasomotor tone, was reported for the first time by Schretzenmayr in 1933. However, 
the mechanism of flow-induced relaxation is still under investigations with an especial 
interest into the molecular mechanisms of transduction of shear stress forces into the 
cellular response.  
 
Shear stress stimulates ECs and initiates the mechanotransduction process. 
Mechanotransduction serves as concerting action, which is initiated by mechanical 
deformation of ECs with following intracellular transmission of stress and conversion 
of mechanical force into chemical activity. Finally, downstream biochemical signaling 
leads to physiological responses (Li et al., 2005; Lehoux et al., 2006; Davies, 2009).  
 
Shear stress is determined by three variables: blood velocity, blood viscosity, and 
vascular diameter.  When the diameter is reduced, or when blood velocity or viscosity 
is elevated, the shear stress imposed on the endothelium is increased. The general 
approach of flow-induced regulation serves as the normal positive feedback mechanism 
of greater blood flow causing greater shear stress, which in turn has a remodelling 
effect to normalize shear stress by relaxation, and thereby allowing greater blood flow. 
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The role of the endothelium-derived factors in flow-induced responses was established 
50 years after discovery of flow-dependent vasoregulation (Hull et al., 1986) Now it is 
generally accepted that flow-induced relaxation is an endothelium-dependent process. 
Distal arteries relax in response to tissue metabolites, whereas in proximal arteries 
increased flow induces secondary relaxation through endothelium-dependent 
mechanisms.  
 
Current dogma is that endothelium-derived NO plays a key role in the regulation of 
flow-mediated dilatation in healthy condition (Joannides et al., 1995; Shiode et al., 
1996). Indeed, after application of shear stress, endothelial NO production is enhanced 
twofold to fourfold over basal values and is maintained as long as the stimulus is 
applied (Fleming et al., 2005). 
 
The activation of eNOS by shear stress or with agonist differs in respect to their 
sensitivity to the concentration of extracellular Ca2+. Shear stress induced responses are 
relatively insensitive to changes in intracellular Ca2+ whereas agonist-induced 
responses highly Ca2+-sensitive (Fleming et al., 2001). Indeed, flow-induced NO 
production is a biphasic process. The first phase is Ca2+ dependent process when 
calmodulin binds to eNOS with following rapid dissociation from caveolin and 
subsequent association with HSP-90. This favours to eNOS phosphorylation on most 
known serine residue (Ser 1177) by protein kinase A (Fleming, 2010). Phosphorylated 
eNOS becomes more sensitive to Ca2+ and, at the second phase, eNOS can be activated 
at resting Ca2+ levels. This is so-called “calcium-independent” activation of eNOS in 
response to shear stress, which results in maintained production of NO (Balligand et al., 
2009).  
 
However, flow-induced responses persist in mice lacking eNOS (Huang et al., 2001) 
and multiple mediators are further implicated. PGl2 (Koller et al., 1995) and 
cytochrome P450 metabolites of AA (Miura et al., 2001; Sun D, 2007) can contribute 
to the flow-induced dilatation as well. Recently H2O2 has been introduced as a 
necessary component of flow-induced vasodilatation (Drouin and Thorin, 2009; Kang 
et al., 2009)  or as an alternative mediator replacing NO-mediated mechanism in CVD 
(Phillips et al., 2007; Liu et al., 2011). Moreover, predominance of EDHF-type 
regulation of  flow-induced dilatation has been found in rats born growth restricted 
(Morton et al., 2011).  
 
Thus, flow-induced vasodilatation is an integrated response involving the release of 
several endothelium-derived vasodilator autacoids. Although NO is generally described 
as the primary endothelium-derived relaxing factor, the contribution of other 
endothelium-derived vasodilators should be taken in consideration as well.   
 
1.3.2.2 Response to pressure  
 
Arteries are constantly exposed to blood pressure and cyclic stretching. In response to 
these forces arteries develop the myogenic response, a state of intrinsic constriction of 
SMCs, which is independent of neurohumoral and endothelial influences (Davis and 
Hill, 1999) (Khavandi et al., 2009). Myogenic constriction is an important component 
of basal vascular tone (Hill and Davis, 2007). Myogenic constriction can be considered 
as a background tone preparing the contractile apparatus to contract more or less in 
response to applied stimuli providing the local regulation of blood flow and pressure in 
rapid and efficient manner.  
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Osol et al have described a three-phase model of in vitro arterial myogenic behavior. 
The first phase is characterized by development of tone (myogenic tone; 40–60 
mmHg). The second phase, myogenic reactivity (60 and 140 mmHg), reflects the 
response to changes in transmural pressure. Elevated transmural pressure leads to 
myogenic constriction, whereas reduced pressure leads to myogenic dilatation.  The 
third phase occurs when the vascular wall of the artery is unable to maintain the 
constriction against transmural pressure (above 140 mmHg) known as forced 
dilatation, a complete loss of myogenic tone (Osol et al., 2002).  Only small arteries 
with a relaxed internal diameter <300µm have the property to develop myogenic 
response (Khavandi and Greenstein et al., 2009). Larger and very small arteries possess 
a relatively weak myogenic response. Furthermore, the strength of myogenic response 
varies in diverse vascular beds of animals and human (Davis and Sikes, 1990; Osol et 
al., 1991; Watanabe et al., 1993; Liao and Kuo, 1997; Miller et al., 1997). 
 
The myogenic response first was described by Bayliss at the beginning of the last 
century. Despite intensive investigation for more than 100 years and its physiological 
and pathophysiological significance, the upstream mechanisms that translate pressure 
changes to vascular SMCs contractions are not entirely understood. Currently the 
following sequence of events is considered to be involved in myogenic response. 
Increased intraluminal pressure is conveyed through the ion channels, or membrane 
lipids bilayer itself, or through extracellular matrix-integrin complex. Activation of 
these pathways leads to the opening of non-selective cation channels, membrane 
depolarization and the opening of voltage-gated, L-type Ca2+ channels. The elevated 
level of Ca2+ results in Ca2+/calmodulin-dependent activation of  myosin light chain  
kinase, phosphorylation of the 20-kDa myosin regulatory light chains and leads to 
contractile interaction of actin and myosin (Zou et al., 2000; Hill et al., 2006; Hill et al., 
2009). More likely, these pathways are activated in parallel and interact with each 
other. 
 
The outcome of pressure-induced responses depends from the duration of exposure of 
vascular wall to the increased intraluminal pressure. After prolong exposure, an acute 
contractile state is eventually replaced by structural alterations within the vascular wall 
known as pressure related remodelling (Mulvany, 2011). Eutrophic inward remodeling 
is characterized by reduction in internal diameter with an increase in wall thickness and 
considered as a physiological response to elevated blood pressure. This type of 
remodelling involves reorganization of the existing elements of the vascular wall and 
may be considered as an intermediated response. Hypertrophic remodelling occurs 
when the ability of artery for autoregularion is depleted and artery is unable to resist the 
increased wall tension any longer. Hypertrophic remodelling is characterized by an 
increase amount of vascular wall tissue, due to SMCs hypertrophy or hyperplasia, and 
indicates a functional disorder and imminent target organ damage.     
      
The physiological relevance of myogenic constriction refers to control the 
microcirculation of target organs, providing a protection of vulnerable organs such as 
brain, heart and kidney from pressure related damage. Therefore, the impact of 
abnormal myogenic responses in the pathogenesis of CVD and protection against 
hypertension-induced organ damage is widely disputed (Davis and Hill, 1999; Hughes 
and Bund, 2002). 
 
To sum up, two mechanical stimuli, flow and pressure, play an important role in the 
local regulation of vascular tone of small arteries. These two most relevant 
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physiological stimuli are applicable for investigation of resistance artery function ex 
vivo in the pressure myography system.    
 
1.4 VASCULAR STRUCTURE AND FUNCTION IN KIDNEY FAILURE  
 
Kidney failure is a worldwide public health problem, with increasing incidence and 
prevalence, high costs, and poor outcomes (Eknoyan et al., 2004). A progressive loss in 
renal function leads to ESRD, end point of chronic kidney disease (CKD) with kidney 
function less than 15% of normal. Clinical evidences show that patients with renal 
failure have a higher prevalence of systemic vascular disease (Agodoa, 2000; Mailloux, 
2001; Kalra et al., 2005). 
 
Despite the rapid progress in dialysis treatment, life expectancy in ESRD patients is 
severely reduced and the major cause of mortality is attributed to CVD (Foley et al., 
1998; Go et al., 2004). Moreover, all existing treatment strategies aimed at reduction of 
CVD such as increased dialysis dose, homocysteine-lowering  therapy,   intensified 
nutrition, lipid-lowering, antihypertensive treatment, and normalization of  
haemoglobin  have not shown a survival benefit (Nanayakkara, 2010). This fact may 
indicate that mechanisms underlying pathophysiology of cardiovascular complications 
of CKD are complex and still far from clear. 
 
Hypertension is diagnosed in the majority of ESRD patients (Agarwal et al., 2003). In 
light of this fact, hypertension can be considered as a major component of the 
relationships between CKD and CVD (Ravera et al., 2006). Altered myogenic activity 
and endothelial dysfunction are closely related to hypertension and cardiovascular 
events in patients with renal failure. Hereby, investigation of structure and function of 
small arteries, which are responsible for the regulation of blood pressure, is of 
importance. Expanded knowledge might provide a new insight into the mechanisms of 
cardiovascular pathophysiology in ESRD. 
 
Until now most of the studies of vascular structure and function in kidney disease have 
been conducted on human large arteries. Increased carotid arterial intima-media 
thickness and stiffness have been reported in patients with kidney failure (Rahn KH, 
2000; Preston et al., 2005; Allison, 2010; Makita et al., 2010). Thickening of the 
intima-media-complex is an early sign of atherosclerosis in big and medium-sized 
arteries. It reduces the distensibility of the arteries during systole. Vascular structural 
alterations tightly correlate with functional abnormalities (Juonala et al., 2004). Indeed, 
endothelial dysfunction is a common phenomenon in patients with kidney disease 
(Passauer et al., 2000; Annuk, 2005; Sahin et al., 2007; Verbeke et al., 2007). 
Moreover, endothelial dysfunction has been detected at an early phase of renal injury 
(Thambyrajah, 2000; Kuczmarski, 2011). This can indicate that endothelial dysfunction 
related to renal failure can promote development of CVD and contribute to the 
progression of kidney failure. 
 
Chronic renal failure per se is considered as a state of NO deficiency (Blum, 1998; 
Baylis, 2008). Investigation of mechanisms behind of endothelial dysfunction in large 
arteries has revealed impairment of both NO-and EDHF-mediated pathways depending 
on the vascular beds.  In vivo studies have provided an indirect evidence of impaired 
contribution of NO to flow-induced responses in ESRD patients (Leone et al., 1992; 
Yilmaz, 2005).  
 
 8 
The mechanisms of endothelial dysfunction in renal failure have been studied more in 
details on subtotally nephrectomized rats. A lack  of NO contribution to flow-induced 
relaxation has been observed on isolated femoral arteries, suggesting that other 
endothelium-derived mediators might be involved (Savage et al., 2001). ACh-induced 
relaxation of  superior mesenteric arteries mediated by both NO and EDHF has been 
attenuated (Kimura, 1999). Severe impairment of EDHF-mediated relaxation has been 
shown in carotid arteries (Kohler et al., 2005). 
 
These findings on large arteries leave unaddressed the issue of whether and/or to what 
extent functional and structural abnormalities may occur concurrently in the resistance 
circulation. Unfortunately, the structure of resistance arteries has not been properly 
investigated. A few studies on animals have suggested that uraemic environment 
affects the vascular structure, pointing towards remodelling process in small arteries. A 
substantial increase in the wall thickness of small intramyocardial arteries (Nabokov et 
al., 1999), increased wall/lumen ratio and decreased lumen diameter have been reported 
in cremaster and mesenteric arteries, although no significant changes have been 
observed in cerebral arteries of subtotally nephrectomized rats, compared to 
normotensive controls (New et al., 2004). However, an early investigation has 
suggested that the advanced human uraemia state was not associated with changes in 
vascular morphology in subcutaneous arteries (Aalkjaer, 1986).  
 
Also there are limited and controversial data in respect to functional properties of 
resistance arteries in uraemic environment. Since myogenic constriction depends on 
intraluminal pressure, it is reasonable to assume that hypertensive uraemic environment 
would increase the myogenic constriction and contribute to the increased peripheral 
resistance. Unexpectedly, no changes in myogenic constriction in skeletal muscle 
arteries (New et al., 2003) or even reduction in myogenic response in cerebral (New et 
al., 2003) and in small mesenteric arteries (Vettoretti, 2006) have been reported. 
Unfortunately, so far only data obtained from animal models are available in regards to 
myogenic response in uraemia. 
 
It is important to specify, that in spite of clinical evidences of impaired vascular 
function in renal failure there is still a lack of knowledge regarding to the state of 
endothelial function of small arteries.  So far only one ex vivo study has provided 
evidence of disturbances of endothelial function in human subcutaneous resistance 
arteries.  Reduced response to ACh but preserved response to NO donor have been 
reported in patients with chronic renal failure (Morris et al., 2001). The mechanism 
behind endothelial dysfunction has been only speculated but not addressed. Inconsistent 
results have been reported using in vivo investigation of skin microcirculation.  Stewarl 
et al. have shown impaired endothelial function in ESRD patients without CVD and 
diabetes mellitus (Stewart et al., 2004). In contrast, normotensive patients with chronic 
renal failure had preserved endothelium-dependent and –independent responses 
(Cupisti, 2000).   
 
Too little is known about the mechanisms of endothelial injury in kidney disease at the 
level of resistance arteries. Measurement of forearm blood flow in hemodialysis 
patients has provided an evidence of reduced stimulation of NO in agonist-induced 
endothelium-dependent vasodilatation (Passauer et al., 2005) and suggested  that CYP 
2C9-derived products did not participate in the regulation of arteriolar tone (Passauer et 
al., 2005). Also impaired flow-induced dilatation due to the lack of NO has been 
observed in gracilis skeletal muscle arterioles in rats after subtotal nephrectomy (Bagi, 
2003). 
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Thus, the expected morphological and functional alterations present in the small 
arteries of CKD patients are largely uncharacterized and unexplored. Since correction 
of endothelial dysfunction in uraemic environment can be an attractive topic for 
pharmacological approaches  (Rabelink and Koomans, 1997), comprehensive 
understanding of the pathophysiology of resistance vasculature in CKD might lead to 
the development of new approaches to prevent or ameliorate the microvascular 
abnormalities. 
 
1.5 PREECLAMPSIA: PATHOGENESIS AND VASCULAR TARGETS   
 
1.5.1 Pregnancy-induced cardiovascular alterations  
Normal pregnancy is accompanied by tremendous changes in the maternal 
cardiovascular system in order to provide an adjustment of blood and nutrient supply 
to constantly increasing demands of the growing fetus, placenta and uterus. The 
cardiovascular pregnancy-induced alterations include expansion of blood volume, 
increase of cardiac output, heart rate, and reduction of blood pressure and systemic 
vascular resistance. Indeed, blood pressure falls until 20 weeks of gestation and returns 
to the initial level at term. Moreover, elevated endothelium-dependent relaxation to 
agonists and flow with reduced vasoconstriction to angiotensin II (Ang II) and 
norepinephrine (NE) have been shown in normal pregnancy (Gant et al., 1973; Nisell 
et al., 1985; Knock and Poston, 1996). Thus, the physiological adaptation to normal 
pregnancy can be considered as a “stress test” for cardiovascular system in particular 
(Williams, 2003). The vast majority of women go through this test without any 
complications, although some develop PE. 
 
1.5.2 Preeclampsia: definition and clinical syndrome 
 
Preeclampsia is a disorder specific to human pregnancy and diagnosed in the presence 
of hypertension (i.e. blood pressure ≥140/90 mmHg after 20th week of gestation in 
previously normotensive women) accompanied by proteinuria (≥300mg in 24-h urine 
sample) (Sibai et al., 2005). Up to 5-7% of pregnancies worldwide are complicated by 
PE (Walker, 2000; Sibai, 2003) and continues to be one of the leading causes of 
maternal and fetal  morbidity and mortality with 15-20% of the total maternal 
mortality in developed countries (Sibai and Dekker et al., 2005), whereas in 
developing countries maternal mortality is more common (up to 3 times higher), 
accounting for 50000 deaths yearly (Duley, 1992).   
 
The most common form of PE is late-onset PE (>34 weeks) with relatively slow 
progression and without many subjective symptoms or related pathologies. Early-onset 
PE (i.e. <34 weeks) is usually more severe form causing maternal and fetal morbidity 
with increased risk for intrauterine growth restriction (IUGR). This form of PE, 
especially if recurrent in subsequent pregnancies, may include impairments in liver 
and kidney functions, coagulation and central nervous system and be related to 
maternal chronic diseases such as thrombophilia and renal failure (Sibai and Dekker et 
al., 2005).  
 
The majority of clinical symptoms usually disappear already after delivery. Therefore, 
it is difficult to distinguish a link between complicated pregnancy and cardiovascular 
health in later life.  
 
 10 
1.5.3 Pathogenesis of preeclampsia 
 
Despite of intensive research, the pathogenesis of PE is still not completely clear. 
Nowadays the most accepted is a two-stage theory of PE pathogenesis (Figure 1.1), 
which considering the presence of reduced placental perfusion as the first stage, and 
following maternal response to abnormal placentation as the second stage (Mutter and 
Karumanchi; Ness and Roberts, 1996; Pijnenborg et al., 2006). Indeed, in the majority 
of cases PE is characterized by abnormal placentation. It is generally assumed that poor 
placental perfusion in PE is a result of shallow cytotrophoblast invasion and the failure 
of maternal uterine spiral artery to undergo normal remodelling. In healthy pregnancy 
the remodelling of spiral arteries results in increased vascular luminal diameter up to 
four times and vascular wall sheds the smooth muscle and the inner elastic lamina 
(Whitley and Cartwright, 2010). The absence of vascular wall components tenders 
these vessels unable to respond to vasoactive stimuli (Roberts and Gammill, 2005). So 
in general, remodelling is modification of vessels to flaccid tubes, which provide a low 
resistance and high blood flow to meet the oxygen and nutrients needs for the 
developing fetus/placenta/uterus. 
 
 
 
 
Figure 1.1. Two stage model of the pathophysiological changes associated with 
preeclampsia. 
 
 
This process is aberrant in PE and, as a consequence, the poor placental perfusion 
occurs. The increased resistance in arteries supplying the intervillous space of women 
with PE was estimated by Doppler velocimetry assessment (Papageorghiou et al., 2002 
).  The development of severe PE in women suffering from molar pregnancies confirms 
importance of the placenta rather than fetus in the pathogenesis of PE (Soto-Wright et 
   11 
al., 1995).  However, decreased placental perfusion might be necessary condition but it 
is not always sufficient for the development of PE.  In clinical practice there are cases 
of PE without alterations in the placental perfusion (Roberts and Lain, 2002).   
Moreover, poor placentation is not a prerogative of only PE. Failure of normal 
placentation has been found in one-third of pregnancies ended by spontaneous preterm 
delivery (Arias et al., 1993), in non-hypertensive cases of IUGR (Khong et al., 1986 ), 
non-proteinuric gestational hypertension, chronic hypertension and exceptionally even 
in entirely normal pregnancies (Pijnenborg and Vercruysse et al., 2006). Perhaps 
variety of pregnancy-related pathology and heterogeneous genesis of PE could be 
explained by multiplicity of maternal health conditions (including genetic, life style and 
environment components), which interact with a certain extent of abnormalities in 
placentation. Possibly the minimal alteration in placentation may lead to PE in women 
with strong susceptibility and the other way around (Roberts and Gammill, 2005). That 
is why the current conception of the heterogenous causes of PE is spread (Ness and 
Roberts, 1996). 
 
Thus, the other component completing the development of PE is a maternal response to 
abnormal placentation. According to the two-stage theory, abnormal placentation must 
interact with maternal factors to result in the PE syndrome (Figure 1.1). Abnormal 
placentation leads to imbalance between constantly growing requirements of 
fetus/placenta/uterus and the limited abilities of placenta to give a necessary blood 
supply to fetus/placenta/uterus. Additionally, it was suggested that the ischemic 
placenta secrete soluble substances into maternal circulation, which are responsible for 
the symptomatic phase of PE, hallmarked by widespread maternal endothelial 
dysfunction. Among most well characterized factors in pathology of PE, the anti-
angiogenic protein soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), 
agonistic Ang II type-1 receptor autoantibodies (AT1-AA), inflammatory cytokines and 
oxidative stress, are of importance. 
 
1.5.3.1 Angiogenic factors 
 
Angiogenesis has a significant role in the placental development. Angiogenic factors 
are thought to be important in the pathogenesis of PE. Ligands and receptors of 
vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) are 
vital in the regulation of angiogenesis (Keck et al., 1989; Maharaj et al., 2006) (Park et 
al., 1994).  
 
Receptors of VEGF (VEGFRs), VEGFR-1 (Flk-1) and VEGFR-2 (KDR/Flk-1), 
predominantly involved in the regulation of blood vessels angiogenesis and expressed 
primarily on ECs. VEGFR-1 binds both VEGF and PlGF, whereas VEGFR-2 is 
specific to VEGF (Zachary, 2003). In pathogenesis of PE the growing interest focused 
on the soluble VEGF receptor-1 (sVEGFR-1, also known as sFlt-1). sFlt-1 is an 
endogenous protein produced by the placenta. sFlt-1 acts as a potent inhibitor of both 
VEGF and PlGF activity by binding them in the circulation and by this way preventing 
their interaction with endogenous receptors and as a result neutralizing their functions.  
 
It has been suggested that an imbalance between pro-angiogenic and anti-angiogenic 
factors might be associated with the pathogenesis of PE. Indeed, the exaggerated level 
of sFlt-1 and low concentrations of free VEGF and PlGF are registered in serum of 
women with PE (Levine et al., 2004) (Shibata et al., 2005; Wikström et al., 2007). It 
has been confirmed that sFlt-1 level begin to rise about five to six weeks before the 
onset of clinical manifestation of PE (Maynard SE, 2003; Hertig et al., 2004) and it is 
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correlated with the severity of PE (Chaiworapongsa et al., 2004; Levine and Maynard 
et al., 2004). Moreover, recent data have shown association between alterations in 
angiogenesis and maternal endothelial dysfunction in women with PE (Sandrim et al., 
2008).   
 
The role of sFlt-1 in pathogenesis of PE is supported by animal studies. Administration 
of sFlt-1 to pregnant rats induced all clinical symptoms of PE - hypertension, 
proteinuria and glomerular endotheliosis (Maynard et al., 2003). The increased level of 
sFlt-1 has been found also in reduced uterine perfusion pressure (RUPP) model of PE 
(Gilbert et al., 2007; Makris et al., 2007).  
 
The role of another circulating factor, sEng, in pathogenesis of PE has been suggested 
recently (Venkatesha et al., 2006). sEng is a co-receptor for transforming growth factor 
β (TGF-β), which prevents TGF-β binding to cell surface receptors and decreases 
endothelial NO signaling. sEng is produced by the ischemic placenta and significantly 
elevated in PE with a pattern similar to that for sFlt-1. The circulating sEng level is 
strongly correlated with severity of clinical signs of PE and its level was markedly 
increased already 2-3 months before the onset of PE (Levine et al., 2006). 
 
There is growing evidence that VEGF, PlGF, and TGF-β are required for ECs 
maintenance in several tissues, including kidney and placenta. Enhanced placental 
secretion of sFlt1 and sEng inhibits VEGF and TGF-β1 signalling in the vasculature of 
women with PE. This results in endothelial dysfunction. It should be noted that 
combined interaction of sFlt-1, PlGF, and sEng characterizes pathogenesis of PE better 
than any of them separately (Lim et al., 2008). Since the importance of VEGF, PlGF, 
sFlt-1, and sEng in pathogenesis of PE has been confirmed, these proteins could be 
targeted as a screening tool for prediction of PE and eventually for pro-angiogenic and 
anti-angiogenic therapies (Tjoa et al., 2007).  
 
1.5.3.2 Angiotensin II type I receptor agonistic autoantibody  
 
Ang II plays multiply roles in the pathology of PE, including contribution to 
hypertension, increased oxidative stress via production of superoxide anions, and 
activation of platelets (Shah, 2005). Several maternal symptoms of PE, i.e. 
hypertension and renal damage, could be attributed to an enhanced activation of Ang II 
receptor type 1 (AT1). However, it was a puzzling feature that the circulating Ang II 
levels were decreased in women with PE compared to normotensive pregnant women 
(Gant and Daley et al., 1973; Gant et al., 1980) (Shah, 2006). This contradiction was 
explained after discovery of the autoimmune antibody against the second extracellular 
loop (165–191) of AT1 receptor (AT1-AA) (Wallukat et al., 1999).  
 
A number of recent studies have demonstrated elevated concentrations of AT1-AA in 
serum from women with PE in comparison with normal pregnancies (Xia et al., 2007; 
LaMarca et al., 2008; LaMarca et al., 2009). The AT1-AA was also detected in women 
with a history of PE up to 18 months after delivery (Hubel et al., 2007). Moreover, 
injection of immunoglobulin G (IgG) or purified the AT1-AA from PE women into 
pregnant mice induced hypertension and kidney damage (Zhou et al., 2008). Both 
placental ischemia and elevations of tumor necrosis factor-alpha (TNF-α) are 
considered as main stimuli for increased production of the AT1-AA (LaMarca et al., 
2011). In experimental models of PE (the infusion of TNFα to RUPP rats) the levels of 
AT1-AA in the circulation was comparable with those in women with PE (LaMarca 
and Wallukat et al., 2008). 
   13 
 
It appeared that AT1-AA has agonist-like effects and may be a reason for excessive 
AT1 receptor activation and could serve as a mediator of vascular injury in 
hypertension and PE (Yang et al., 2008). AT1-AA may cause hypertension by direct 
activation of AT1 receptors, whereas in PE additional pathways involving ET-1 and 
anti-angiogenic factors may also be implicated (LaMarca and Parrish et al., 2009). 
Indeed, a close association between enhanced production of AT1-AA, sFlt-1, sEng and 
placental oxidative stress has been demonstrated in animal studies (Zhou et al., 2008; 
Parrish et al., 2010; Parrish et al., 2011), although clinical data are fractional and 
controversial. Stepan et al. have failed to find the correlation between AT1-AA and 
sFlt-1 concentrations in women with PE (Stepan et al., 2006). However, more recent 
study has confirmed a strong positive correlation between serum concentration of AT1-
AAs and sFlt-1 levels in women with severe PE (Siddiqui et al., 2010).  
 
Current hypothesis is that chronic immune activation in association with placental 
ischemia leads to sFlt-1 and sEng overexpression via stimulation of the AT1-receptor 
possibly by production of the AT1-AA (LaMarca and Wallace et al., 2011). Thus, the 
potential role of AT1-AA in the development of hypertension in women with PE is a 
complex interaction between inflammatory, angiogenic and endothelial mediators 
produced excessively in response to placental ischemia.  
 
1.5.3.3 Oxidative stress, inflammatory and metabolic responses 
 
PE is associated with enhanced oxidative stress and exaggerated systemic inflammatory 
and metabolic responses. These states are closely interrelated. The activation of 
leukocytes in the circulation and increased their adhesion to ECs increases oxidative 
stress in PE, and vice versa, reactive oxygen species from other sources can initiate the 
inflammatory response. Indeed, hypoxia-induced transcription factor NF-kappaB and 
oxidative stress control inflammatory response (Li and Karin, 1999).  Moreover, 
inflammation can trigger the metabolic changes, including insulin resistance and 
dyslipidemia with following increase of oxidative stress.  
 
Increased oxidative stress due to the imbalance between lipid peroxidation and 
antioxidant defense mechanisms is a feature of PE. Indeed, maternal circulating and 
placental tissue levels of reactive oxygen species, and production rate of lipid 
peroxides are increased whereas several antioxidants are markedly decreased in 
women with PE (Siddiqui et al., 2010).   
 
Oxidative stress in the placenta results in widespread placental lipid and protein 
oxidative modifications, mitochondrial and endoplasmic reticulum stress, tissue 
apoptosis and necrosis (James et al., 2010). Thus, oxidative stress further increases the 
damage of placenta and plays an important role in reduced placental perfusion in PE. 
However, the oxidative stress in PE is not localized to the placenta but disseminated 
into the maternal circulation and is a part of the systemic inflammatory response. 
Therefore, oxidative stress was postulated as the link between the early and late stages 
of the pathophysiology of PE (Roberts and Hubel, 1999). While the evidence provides 
a strong rationale for the therapy with antioxidants in PE, relatively recent trials of 
vitamins C and E in a number of different settings have not been successful (Poston L, 
2006; Roberts et al., 2010; Xu et al., 2010). 
 
Despite the immune system has a potential role in spiral artery remodelling in the first 
trimester, the systemic inflammatory stress plays also an important role in the 
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pathogenesis of PE in the third trimester (James and Whitley et al., 2010). Indeed, poor 
placentation increases the level of trophoblast debris into the maternal circulation, 
which elicits an increase inflammatory response and leads to endothelial dysfunction 
(Sargent et al., 2003). In PE both monocytes and granulocytes are activated with 
following increased adhesion to ECs and released of pro-inflammatory cytokines into 
the circulation (Janes and Goodall, 1994; Conrad et al., 1998; Sargent et al., 2006). It 
has been reported the higher circulating levels of TNF-α, IL-6, and  IL-8  but the 
decreased IL-10 levels in PE compared to healthy pregnancy (Vince et al., 1995; Ellis 
et al., 2001) (Hennessy et al., 1999; Sharma et al., 2007) (Fabiana et al., 2008).  
 
Finally, PE has many characteristic in common with the metabolic syndrome. The 
metabolic syndrome of PE includes hypertension, insulin resistance, complex changes 
in lipid profile, and inflammation (Sattar N, 1997; Hubel et al., 1998; Belo et al., 2002; 
Llurba et al., 2005) (Newstead et al., 2007). The same level of metabolic alterations are 
peculiar for atherosclerosis and reveal high risk for coronary artery disease (Carmena et 
al., 2004). Since, elevated fasting insulin and glucose levels as well as proatherogenic 
lipid profile occur even before clinical manifestation of PE (Endresen et al., 1994) 
(Malek-Khosravi and Kaboudi, 2004), metabolic-mediated endothelial dysfunction has 
been considered as one of the major pathogenic pathway of PE for many years.  
 
1.5.4 Maternal vascular dysfunction in preeclampsia 
 
Several vascular changes have been reported in PE. Increased sympathetic tone has 
been shown in women with PE in comparison with normotensive pregnant and 
hypertensive non-pregnant women (Schobel et al., 1996; Stennett and Khalil, 2006 ). A 
higher constriction in response to NE (Nisell and Hjemdahl et al., 1985) and enhanced 
sensitivity to Ang II (Brown et al., 1997) were demonstrated in arteries of women with 
PE.  
 
As soon as endothelial role in the control of arterial tone has been appreciated the 
investigations of vascular abnormalities during PE have been focused on endothelial 
dysfunction.  Currently, endothelial dysfunction is considered as end-point of 
pathophysiological processes of PE and a key event in cardiovascular complications. 
Indeed, the primary clinical manifestations of PE such as hypertension, renal 
dysfunction and proteinuria, and edema in one way or another can be linked to 
alterations of endothelial function. The role of placental factors in this pathology seems 
to be significant. The factors produced by a poor oxygenated placenta may cause 
endothelial dysfunction due to imbalance between release of endothelium-derived 
relaxing and constricting factors with predominance in secretion of substances with 
vasoconstrictive properties (i.e., ET-1 and TX A2) (Clark et al., 1992; Mills et al., 
1999).  
 
Endothelial dysfunction is accompanied by activation of coagulation cascade, increased 
vasoconstriction and intravascular fluid redistribution. This leads to reduce organ 
perfusion in the uterus (Roberts and Gammill, 2005)  with secondary reduction of 
blood flow to the placenta/fetal unit (Pijnenborg and Vercruysse et al., 2006) creating a 
forward feedback cycle loop.   
 
Several evidences of endothelial dysfunction in PE have been accumulated in the 
literature for the last decades. First of all, the presence of factors released by the 
injured or activated endothelium in the circulation of women with PE is well 
established. Indeed, increased circulating levels of von Willebrand factor (vWF, an 
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activator of platelet adhesion), tissue plasminogen activator (tPA, a fibrinolysis 
inhibitor), plasminogen activator inhibitor-1 (PAI-1), ET-1, cellular fibronectin, 
soluble vascular cell adhesion molecule, thrombomodulin and increased growth 
factor activity are reported in women with PE and altogether can be considered as 
remarkable evidences of endothelial disturbances or activation (Roberts et al., 1989; 
Friedman et al., 1995; Hayman et al., 1999 ). Some markers of endothelial 
dysfunction and activation have been noticed even before the clinical features of the 
PE.  
 
Endothelial dysfunction in PE is confirmed by several functional studies on arteries 
from different vascular beds; although the heterogeneity in responses between studies 
should be noticed here as well. In general, reduced endothelium-depended relaxation 
to ACh, BK and flow was shown in diverse small arteries in vitro. Namely, attenuated 
endothelium-dependent responses to BK, ACh and shear stress were reported in 
subcutaneous arteries from women with PE (Cockell and Poston, 1997) (Knock and 
Poston, 1996) (McCarthy et al., 1993). In contrast, similar responses to ACh and BK 
between normal pregnancy and PE or abolished ACh-, but preserved substance P-
induced dilatations have been reported in subcutaneous arteries as well (VanWijk et 
al., 2002; Wimalasundera et al., 2005). 
 
Also endothelial dysfunction was reported in omental arteries from women with PE 
(Pascoal et al., 1998; Suzuki et al., 2000; Suzuki et al., 2002). However, there was 
inconsistence between the studies and reduced endothelium-dependent responses to 
ACh but preserved to BK in one study   (Pascoal and Lindheimer et al., 1998) 
contrasting with reduced responses to BK in another one (Suzuki and Kajikuri et al., 
2000).  
 
The controversial results were obtained on myometrial arteries as well. Using a wire 
myography technique a significant reduction of endothelium-dependent relaxation to 
BK has been shown in PE (Ashworth et al., 1997; Wareing et al., 2004; Wareing et 
al., 2006). However, after utilization of the pressure myography technique, Kenny et 
al. (2002) failed to reproduce the results (Kenny et al., 2002). In contrast, reduced 
response to BK (Svedas et al., 2002) and the lack of flow-induced dilatation 
(Kublickiene et al., 2000) were found in  our laboratory. Thus, the discrepancy in 
results obtained in small arteries from different vascular beds in PE and between 
different research groups deserves consideration and requires further investigation.   
 
Moreover, in contrast to above mentioned in vitro studies, the measurements of 
microcirculatory response in skin by laser Doppler perfusion monitoring and 
iontophoresis of ACh showed better endothelium-dependent response in women with 
PE compared with healthy pregnant women (Eneroth-Grimfors E, 1993; Davis et al., 
2001).  
 
Whereas endothelial dysfunction associated with PE at level of small arteries is 
generally appreciated, currently the main discussion is about possible mechanisms 
involved. Studies showing that serum from women with PE induce endothelial injury 
in vitro support the theory that circulating factors cause the endothelial dysfunction 
(Myers et al., 2005). Although abnormalities in every endothelium-derived factor are 
reported in PE (Bird et al., 2003; Gillham et al., 2003; Poniedzialek-Czajkowska et al., 
2011), there are not enough evidences so far to make a clear statement about 
predominant contribution of NO, PGl2, and EDHF into compromised endothelium-
depended relaxation of small human arteries in PE. 
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1.6 LONG TERM CONSEQUENCES OF PREECLAMPSIA 
 
The hypothesis that women with a history of PE are more prone to CVD later in life has 
been originated long time ago. As early as 50 years ago the first investigation of 
previously PE women was performed in order to estimate the effect of PE on blood 
pressure later in life (Adams and MacGillivray, 1961). For the following half a century 
a number of studies have been carried out worldwide to investigate the relationship 
between PE and long-term cardiovascular consequences such as hypertension, ischemic 
heart disease, stroke, and venous thromboembolism, diabetes Mellitus, renal disease as 
well as cancer.  
 
Recently, Bellamy el al  conducted meta-analysis where overall 25 prospective and 
retrospective cohort studies were included (Bellamy et al., 2007). Those studies 
numbered 29 459 incident cases of CVD from 198 252 cases of PE. The control group 
included over 3 million women. It was summarized that a history of PE enhances risk 
of  CVD in follow-up of 10-14 years (Bellamy and Casas et al., 2007). The relative risk 
(RR, 95% confidence intervals (CI)) for hypertension was 3.70 (2.70 to 5.05); for 
ischemic heart disease 2.16 (1.86 to 2.52), for stroke 1.81 (1.45 to 2.27) and for venous 
thromboembolism 1.79 (1.37 to 2.33) compared with women who have had healthy 
pregnancies. These findings have not been adjusted for the severity and recurrence of 
PE and/or fetal outcome.  In parallel with estimation of long-term effects of PE on 
CVD, no association between PE and future breast cancer has been found. 
 
More recent meta-analyses has included 5 case-control studies and 10 cohort studies, 
involving a total of 118 990 women with a history of PE/eclampsia and 2 259 576 
women with a history of uncomplicated pregnancies (McDonald et al., 2008). The 
risk of CVD appeared to relate to PE severity. Thus, the RR (95% CI) was 2.00 (1.83-
2.19) for mild PE, 2.99 (2.51-3.58) for moderate PE and 5.36 (3.96-7.27) for severe 
PE (complicated by preterm delivery and/or fetal death) (McDonald and Malinowski 
et al., 2008). 
 
Analyzing more than one million delivers, Lykke et al. have shown strong association 
between PE and subsequent hypertension. Besides of the severity, parity and recurrence 
of PE increased the risk of subsequent hypertension. Thus, women having 2 
pregnancies both complicated by PE had a 6.00-fold (5.40 to 6.67) increased risk of 
subsequent hypertension compared with 2.70-fold (2.51 to 2.90) for women having PE 
in their first pregnancy only and 4.34-fold (3.98 to 4.74) for women having PE in their 
second pregnancy only (hazard ratios are presented with 95% CI) (Lykke et al., 2009).  
 
Previous studies have shown that women within 3-7 years after PE have an increase 
incidence of microalbuminuria, a potential marker of both CVD and renal damage 
(Nisell H, 1995; Bar et al., 1999). The recent epidemiological Norwegian study has 
shown that women with previous PE in their fist pregnancy were 4.7 times (3.6-6.1; 
95% CI) more likely to develop ESRD later in life then those with uncomplicated 
pregnancies. The even greater risk was found in those women who had PE in more 
than one pregnancy or in case when PE was complicated by IUGR (Vikse et al., 
2008). 
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In spite that the link of PE and later CVD complications is obvious, relationships 
between causality and consequence are still under discussion. So far we cannot 
answer the question whether residual “damage” from PE induces later life diseases or 
PE unmasks predisposition of women to these diseases, since we have too little 
information available on women health before their PE pregnancy. Nowadays we 
have only indirect evidences, which allow assuming that some women have 
susceptibility to develop PE as well as CVD in later life. Increased pre-pregnancy 
serum levels of triglycerides, cholesterol, LDL cholesterol, non-high density 
lipoprotein cholesterol, and blood pressure were associated with an increased risk for 
developing of complications in their pregnancies. The odds ratio (95% CI) for 
developing of PE in women with baseline systolic blood pressures greater than 130 
mm Hg  was 7.3 (3.1 to 17.2) compared with normotensive  women independently 
from the parity (Magnussen et al., 2007). This suggests that women with prevalence 
of cardiovascular risk factors may manifest clinical symptoms of PE in their 
pregnancy.  
 
Hereby at this stage, the pregnancy should be considered as a screening test for later 
life CVD/ESRD.  Therefore, health of women with a history of PE has to be 
supervised regularly later on, since they failed ones the pregnancy test and may be 
considered as a risk group. 
 
1.6.1 Endothelial function in follow-up preeclampsia 
 
Even if PE appears to begin in the placenta, the target maternal organ is endothelium. 
The epidemiological evidences of the link between PE and increased prevalence of 
CVD later on has drawn an interest to investigations of vascular function in women 
experienced PE.  The high level of cardiovascular abnormalities among these women 
could be referring to a generalized maternal endothelial dysfunction. Few studies have 
been performed to determine if endothelial dysfunction persists after the PE 
pregnancy. The data of in vivo studies are summarized in Table 1. The postpartum 
period from months to 25 years has been covered and different technical approaches 
have been used. It should be noted that heterogeneity of PE groups (combination of 
early or late onset of PE in the same group) is a feature of majority of studies. As a 
consequence, the available results are contradictory. 
 
Noninvasive measurement of arterial elasticity might be considered as an indirect 
method for evaluation of endothelial function as well. It is well accepted that reduced 
arterial elasticity is associated with endothelial dysfunction. An increase in arterial 
stiffness has been documented in high vascular risk conditions such as hypertension 
(McVeigh et al., 1991), diabetes mellitus (Dogra et al., 2006) and CKD (Wilson et al., 
2004). Furthermore, arterial stiffness has been shown to be strongly associated with an 
increased cardiovascular risk (Boutouyrie et al., 2002) (Laurent S, 2007; Vlachopoulos 
et al., 2010).   
 
Studies in women with a history of PE have reported conflicting results indicating 
either no difference in arterial compliance (Rönnback et al., 2005; Spasojevic et al., 
2005; Lampinen KH, 2006)  or an increase of arterial stiffness  (Elvan-Taspinar A; 
Pàez et al., 2009; Robb et al., 2009; Yinon et al., 2010; Souwer et al., 2011). Such 
inconsistency might be due to the fact, that these studies assessed different parameters 
of arterial stiffness without comprehensively adjusting for all known confounding 
variables such as blood pressure, heart rate, body mass index (BMI), postpartum time 
frames, heterogeneity of PE and etc.   
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Thus, although until now a number of studies for direct or indirect evaluation of 
endothelial function in women with a history of PE were conducted, the inconsistency 
in the results and heterogeneity of recruited participants have limited the significance of 
the obtained data. Therefore, more investigations of vascular function in the well 
defined group of women with a history of PE adjusted for the postpartum period and 
the severity of PE are still needed. Moreover, there are no studies so far for 
investigation of vascular function on isolated arteries from women with a history of PE.  
Such type of investigation could help to distinguish the alterations within the vascular 
wall vs. systemic changes observed in these women and eventually understand the 
mechanisms of dysfunction restricted to the vascular wall performance. 
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2 AIMS  
 
The general aim of the investigations summarized in this thesis was to extend the 
current knowledge about structural and functional properties of human resistance 
arteries with particular focus on endothelial regulation of vascular tone and the 
mechanisms of endothelium-dependent dilatation in health and disease.  
 
 
The specific aims of the ex vivo studies were:  
 
Study I:  
 
• To investigate structural (wall thickness, wall/lumen ratio and CSA) and 
functional (dilatation, constriction and elastic properties) characteristics of 
subcutaneous resistance arteries from ESRD patients;  
• To examine the role of NO in flow-induced responses in resistance arteries 
from ESRD patients vs. controls;  
• To understand the potential mechanism/s of endothelial dysfunction in ESRD.  
 
 
Studies II-III:  
 
• To assess the endothelial function of subcutaneous and myometrial resistance 
arteries from women with preeclampsia; 
• To compare the relative contribution of EDHF vs. NO into overall 
endothelium-dependent dilatation between arteries from women with vs. 
without preeclampsia; 
• To clarify the specific mechanisms involved in EDHF-mediated relaxation in 
preeclampsia.  
 
Study IV:  
 
• To investigate structural (wall thickness, wall/lumen ratio and CSA) and 
functional (dilatation, constriction and elastic properties) characteristics of 
subcutaneous resistance arteries from women with a history of early-onset 
preeclampsia; 
• To examine the role of NO in dilatation and constriction of resistance arteries 
from women with a history of early-onset preeclampsia vs. women with a 
history of normal pregnancy.  
  
   23 
3 MATERIALS AND METHODS 
 
Three main groups of participants were included in this thesis. Each group contained 
two subgroups: case (ESRD patients, Study I; pregnant women with PE, Studies II-III; 
volunteers with history of severe early-onset PE, Study IV) and matched controls. The 
Ethical Committee at Karolinska University Hospital, Stockholm approved the 
protocols for all studies.  All participants gave writing informed consent prior to tissue 
biopsy and blood collection. Figure 3.1. summarizes the number of the subjects 
included in the studies, used material and applied methods. 
 
 
 
Figure 3.1. Study design: distribution of participants, materials and applied methods 
within the project. ESRD, end-stage renal disease; PE, preeclampsia; pPE, previous 
preeclampsia. 
 
3.1 PARTICIPANTS 
 
Study I. Thirty five ESRD patients (median age 58 years; 71% males) who underwent 
peritoneal dialysis catheter insertion were recruited at the Division of Renal Medicine 
at Karolinska University Hospital, Huddinge. In order to establish homogeneity, only 
patients starting dialysis treatment de novo were included. Thirty gender-matched 
volunteers (median age 54 years; 77% males) who underwent a surgery for hernia 
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repair or laparoscopic cholecystectomy were recruited as controls at the Division of 
Surgery at Karolinska University Hospital, Huddinge.  
 
Clinical history of CVD or diabetes and medical treatments were obtained from 
medical records. CVD was defined as the presence of ischaemic cardiac disease, 
peripheral vascular disease and/or cerebrovascular disease. Blood pressure and 
smoking status were recorded.  
 
Studies II-III.  Nineteen women with PE pregnancies (8 women included in both 
studies plus 7 women for Study II and 4 for Study III) and 35 women with normal 
pregnancies (23 in Study II and 12 in Study III) were recruited from the Division of 
Obstetrics and Gynecology at Karolinska University Hospital, Huddinge. PE was 
defined according to the criteria of the International Society for the Study of 
Hypertension in Pregnancy. Diagnosis required blood pressure ≥140/90 mmHg after 
the 20th week of gestation in association with >300 mg proteinuria in a 24-h urine 
collection. Two women with PE fulfilled the criteria for HELLP syndrome (hemolysis, 
elevated liver enzymes, and low platelet count). Biopsies were obtained during 
emergency cesarean delivery due to deterioration of PE. All women from the control 
group were delivered by elective cesarean section due to previous cesarean delivery 
(n=10), psychological reasons (n=15), and breach presentation (n=10). None had any 
history of diabetes mellitus, abnormal renal or hepatic function, established 
hypertension and atherosclerosis, malignancy, systemic infection, vasculitis, and recent 
surgery or trauma.  
 
Study IV. Women with last singleton pregnancy complicated by severe early-onset 
(delivery at ≤ 34 weeks of gestation) PE, who had delivered between years 2007 and 
2010 were included in the study.  Severe PE was defined (based on the international 
classification of diseases (ICD-10) as blood pressure ≥160/110 mmHg on 2 occasions 
at least 6 hours apart and/or proteinuria of more than 5 g in a 24-hour urine collection 
and/or organ damage (ICD-10). Twelve women experienced uncomplicated singleton 
pregnancies matched for age, BMI, smoking status and time after delivery comprised a 
control group.  Exclusion criteria for both groups were: age ≥45 years,  ongoing 
pregnancy, CVD, obesity, diabetes mellitus, chronic hypertension, malignancy, hepatic 
or renal disease, systemic infection, vasculitis, venous thromboembolic disease, recent 
surgery, trauma or presence of hormonal contraception. Majority of women included in 
the study were in the early follicular phase of the menstrual cycle.  
 
The participant’s information regarding to previous pregnancy and family history of 
preeclampsia and CVD were collected. Height and weight were recorded. Waist 
circumference was measured halfway between the rib cage and the pelvic bone. Hip 
circumference was measured at the maximal circumference of the hips. BMI, waist-to-
hip ratio were calculated. Blood pressure was measured twice using a sphygmanometer. 
The mean of these two measurements was used in the analyses. 
 
 
3.2 MATERIALS 
 
3.2.1  Blood samples 
 
Blood samples were collected after an overnight fast. Plasma samples and serum were 
stored at −70◦C pending further analyses. 
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Study I. Glomerular filtration rate was estimated by the mean of creatinine and urea 
clearances in ESRD, whereas cystatin-C was used to estimate glomerular filtration rate 
in controls. Serum IL-6 was measured on an Immulite® analyser (Siemens Medical 
Solution Diagnostic). Circulating ADMA was assessed in serum using commercial 
ELISA assays (DLD Diagnostika). Serum concentrations of albumin (by the 
Bromocresol Purple method), creatinine, haemoglobin, blood lipids and high sensitivity 
C-reactive protein (hsCRP) were measured by routine procedures at the Department of 
Clinical Chemistry at Karolinska University Hospital-Huddinge.  
 
Study IV. Biochemical analyses of blood included estimation of lipid profile, glucose 
homeostasis, inflammation, homocysteine. Urine albumin, creatinine and 
albumin/creatinine ration were detected. 
 
3.2.2 Artery preparation 
 
Subcutaneous fat or myometrial biopsies (≈ 2×1.5×1.5 cm), in accordance with study 
design, were obtained from the participants. Removed biopsy was immediately placed 
into an ice physiological salt solution (PSS). Small subcutaneous and/or myometrial 
arteries (≈200µm) were identified and dissected from the biopsies by carefully 
removing surrounding tissue using a stereomicroscope. The dissected arteries were 
divided into segments with a length of approximately 2 µm for mounting in the wire-
myography system and approximately the same length but with particular control for 
the lack of branches for mounting in the pressure myography systems. 
 
3.3 METHODS 
 
3.3.1 Pressure myography 
 
The arterial segments were oriented to mimic the direction of flow in vivo and mounted 
between two glass microcannulae in a pressure myograph chamber (Living Systems 
Instrumentation Inc., USA; Figure 3.2.a). Intraluminal pressure (60 mmHg) was 
maintained by a servo-controlled pump. The constant pressure in the system confirms 
the absent of arterial leakage, otherwise the leaked arteries were discarded. The 
dimensions of the cannulated artery (internal diameter and wall thickness) were 
continuously monitored via a video dimension analyser. The organ bath was superfused 
with ≈37°C PSS gassed with 5% CO2 in O2. Each artery was equilibrated for 60 min. 
The viability tests were carried out by examining the responses to NE (1 µmol/l), and 
endothelial function was confirmed by relaxation to ACh (1 µmol/l).  
 
3.3.2 Wire myography 
 
Small subcutaneous and myometrial arteries were mounted on two stainless steel wires 
(25–40 µm in diameter) in the organ baths of a four-channel wire myograph 
(multimyograph, model no. 610; Danish Myo Technology; Aarhus, Denmark; Figure 
3.2.b) as described previously (Luksha et al., 2004). Each organ bath contained warmed 
(37°C) PSS and was continuously bubbled with 5% CO2 in O2. Following a 30-min 
equilibration period, a passive circumference-tension curve was created for each 
segment to set optimum resting tension. This resting tension is calculated to simulate an 
in vivo transmural pressure of 100 mmHg. Arteries were then set at 90% of this tension 
to enable optimal contractile conditions with a low resting tension. Calibration and data 
processing were performed using Myodac software (version 2.1, Danish Myo 
Technology). All solutions were refreshed every 30 min. Five reference constrictions 
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were elicited. The first, second, and fifth contractions were produced using a high (124 
mmol/l) potassium physiological salt solution (KPSS, made by equimolar substitution 
of KCl for NaCl in PSS) containing NE (1 µmol/l). The third was obtained with NE (1 
µmol/l) alone and the fourth with KPSS alone. Arteries that failed to produce active 
tension equivalent to 100 mmHg when constricted with KPSS containing 1 µmol/l NE 
were discarded. Arteries that did not fulfill the viability criteria (i.e.>60% relaxation to 
ACh (1µmol/l) after pre-constriction with NE (1 µmol/l)) were discarded from 
experiment. 
 
 a                                                                b          
    
 
Figure 3.2. Arteries mounted in the pressure (a) and wire (b) myographies.  
 
3.3.3 Experimental protocols 
 
3.3.3.1 Assessment of vascular function: flow-mediated dilatation  
 
After the equilibration period, the intraluminal pressure was gradually increased from 
60 to 80 mmHg for arteries with internal diameter >200 µm, and the internal diameter 
was recorded after 20 min. In contrast, for arteries with an internal diameter <200 µm, 
intraluminal pressure was permanently kept at 60 mmHg. A flow response curve to 
stepwise increase of intraluminal flow every 3 min from 0 to 180 µl/min in Study I and 
from 0 to 90 µl/min in Study IV was performed on the pre-constricted artery to ≈50% 
of the initial diameter. In a separate experimental setup in Study I and in all 
experiments in Study IV flow response curves were obtained before and after 
incubation with NO synthase (NOS) inhibitor, Nω-nitro-L-arginine-methyl ester (L-
NAME) (300 µmol/l, 30 min).  
 
3.3.3.2 Assessment of agonist-induced responses on the pressure myography  
 
Equilibrated arteries at 60 mmHg were superfused with NE (1µmol/l) for 20 min in 
order to induce a stable constriction. Concentration-response curves were obtained 
using incremental concentrations of vasodilators ACh (endothelium-dependent agonist, 
3 nmol/l–1 µmol/l) and sodium nitroprusside (SNP, endothelium-independent agonist, 
0.1 µmol/l–0.1 mmol/l) in Study I and vasodilators BK (endothelium-dependent 
agonist, 1 nmol/l–3 µmol/l) and SNP (0.1 µmol/l–0.1 mmol/l) in Study IV. ACh, BK or 
SNP were added in NE-contained PSS. The concentration-response curves using 
incremental concentrations of vasoconstrictors NE (non-selective agonist of adrenergic 
receptors, 1 nmol/l–1 µmol/l), Ang II (0.01nmol/l–30 nmol/l) were assessed in Study 
IV. The concentration-response curves to NE, BK, Ang II were repeated after 
incubation with the NOS inhibitor L-NAME (300 µmol/l, 30 min) in Study IV. Each 
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concentration of the agonist was extraluminally perfused for 3 min, while the changes 
in the diameter were constantly recorded.  
 
3.3.3.3 Assessment of pressure-induced myogenic response and the basal tone 
 
After 20 min artery equilibration at 20 mmHg, intraluminal pressure was gradually 
increased up to 120 mmHg. Internal artery diameter was recorded after each pressure 
increment, which was maintained for 5–7 min in order to reach a steady state diameter. 
Thereafter, PSS was replaced with PSS without Ca2+ (Ca2+-free PSS) to determine the 
passive diameter curve in response to stepwise pressure increase. 
 
To estimate the basal vascular tone at resting condition (at 60 mmHg) internal artery 
diameter was recorded after equilibrated period (60 min) in PSS. As well the passive 
arterial diameter at 60 mmHg was recorded in Ca2+-free PSS. 
 
3.3.3.4 Assessment of arterial distensibility 
 
PSS was replaced for Ca2+ free PSS. Intraluminal pressure was decreased to 5 mmHg 
and after 20 min of equilibration the internal diameter was recorded. Thereafter the 
intraluminal pressure was increased stepwise (10 mmHg pressure increment) up to 120 
mmHg in the Study I and up to 160 mmHg in Study IV. The internal diameter of each 
pressure step was recorded after 2 min.  
 
3.3.3.5 Assessment of agonist-induced constriction on the wire myography in Study I  
 
The cumulative concentration-response curves were constructed for phenylephrine 
(selective agonist of α1-adrenergic receptors, 10 nmol/l–0.03 mmol/l), NE (10 nmol/l–
0.03 mmol/l), Ang II (0.1–30 nmol/l) or ET-1 (0.1–30 nmol/l) before and after 
incubation with the NOS inhibitor L-NAME (300 µmol/l, 30 min).   
 
3.3.3.6 Assessment of BK-induced response and contribution of EDHF to BK-
mediated relaxation in Studies II-III 
 
All arteries were pre-constricted with NE (3 µmol/l) or vasopressin (VP; 3 nmol/l) and 
the concentration-response curves were obtained using incremental concentrations of 
BK (1 nmol/l–3 µmol/l). Arteries were then incubated for 20 min with L-NAME (300 
µmol/l) and the COX inhibitor indomethacin (Indo; 10 µmol/l) to block the production 
of NO and PGI2, respectively. Subsequently, arteries were pre-constricted again and 
concentration-response curve for BK was repeated. The term “EDHF” used in this 
study refers to the L-NAME- and Indo-insensitive component of endothelium-
dependent vasodilatation in response to BK. 
 
Assessment of contribution of AA metabolites, H2O2, and MEGJ to EDHF-type 
responses 
 
To investigate whether AA metabolites played a role as EDHF, the BK-induced 
relaxation was assessed in the presence of the specific inhibitor of CYP450 
epoxygenase (CYP2C9) sulfaphenazole (10 µmol/l, 30 min) in combination with L-
NAME + Indo. 
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To evaluate if H2O2 was involved in the EDHF-typed response, the BK-induced 
relaxation was assessed in the presence of catalase (1250-6250 U/ml, an enzyme, which 
depredates H2O2 forming H2O and O2) in combination with L-NAME + Indo. 
 
To elucidate the contribution of gap junctions to the EDHF-typed response, the 
concentration response curves to BK were obtained after incubation with a reversible 
inhibitor of gap junctions - 18-α-glycyrrhetinic acid (18-αGA, 100 µmol/l, 15 min) in 
combination with L-NAME + Indo. 
 
3.3.4 Immunohistochemistry  
 
Immunohistochemistry (IHC) was used to determine the level of HSPs 90, 70, 27 and 
the oxidative stress marker nitrotyrosine in isolated small subcutaneous arteries from 
patients with ESRD and compared them with controls. The control group was 
composed from the patients included or not included in the functional study. Before the 
experiments, transverse 7 µm cryosections were cut using a cryostate HM 500 M, 
mounted onto Superfrost slides, and stored at –20o C. The experiments were carried on 
in two-day cycles. During the first day the samples were thawed for 5 to 10 min, fixed 
with pre-cooled formaldehyde for 4-5 min. Blocking was carried out with 0.75% H2O2 
in phosphate buffered saline (PBS) and 4% normal goat serum (NGS) in PBS, each for 
30 min incubation time at room temperature. Then the primary antibodies, diluted in 
PBS with 0.1% Tween and 3% NGS were added on the sections and the slides were 
incubated overnight at +4o C. Antibody concentration was 10 µg/ml for anti-HSP90, 
0.66 µg/ml for anti-HSP70 and 20 µg/ml for anti- nitrotyrosine. Negative controls with 
0.1% Tween in 3% PBS and in PBS without primary antibodies were used. During the 
second day, the secondary antibody (5 µg/ml) diluted in PBS with 3% NGS was added 
to the sections.  The slides were incubated for 30 min at room temperature. 
Streptavidin-Biotin Peroxidase solution on 30 min incubation and 3,3'-
Diaminobenzidine (DAB) solution on 2 min incubation were successively added. 
Between each step the slides were washed with PBS, and after the DAB incubation 
they were accurately washed in dH2O. After nuclear staining with 10% hematoxylin for 
2 min the sections were washed with hot running water and dehydrated with increasing 
concentrations of ethanol (70% x 5 min, 95% x 5 min and 99.5% x 10 min), immersed 
in xylene for 15 min and then mounted with Pertex mounting medium. 
 
3.3.5 Transmission electron microscopy  
 
Artery segments were fixed in 2% glutaraldehyde  + 0.5% paraformaldehyde in 0.1 M 
sodium cacodylate buffer containing 0.1 M sucrose and 3 mM CaCl2, pH 7.4, at room 
temperature for 30 min followed by 24 h at 4°C. Specimens were rinsed in 0.15 M 
sodium cacodylate buffer containing 3 mM CaCl2, pH 7.4; postfixed in 2% osmium 
tetroxide in 0.07 M sodium cacodylate buffer containing 1.5 mM CaCl2, pH 7.4, at 4°C 
for 2 h; and dehydrated in ethanol followed by acetone and embedded in LX-112 
(Ladd, Burlington, VT). Semi-thin sections were cut and stained with toludin blue and 
used for light microscopic analysis. Sections were examined in a Tecnai 10 
transmission electron microscope at 80 kV, and digital images were captured by a 
Mega View III digital camera (Soft Imaging System, Muenster, Germany). 
 
3.4 CHEMICALS AND SOLUTIONS   
 
The composition of PSS (mmol/l) was NaCl 119, KCl 4.7, CaCl2 2.5, MgSO4 1.17, 
NaHCO3 25, KH2PO4 1.18, ethylenediamine-tetraacetic acid 0.026, and glucose 5.5; 
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pH 7.4. Relaxing solution was Ca2+-free PSS supplemented with papaverine (0.1 
mmol/l) and ethylene glycol-bis-(β-aminoethyl ether) tetraacetic acid (1 mmol/l). NE 
was dissolved directly in PSS, whereas for ACh, phenylephrine, Ang II, ET-1, SNP and 
sulfaphenazole stock solutions were prepared in distilled water and further dissolved in 
PSS. Indo, ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, selective guanylate 
cyclase inhibitor), pinacidil were dissolved in ethanol, and 18-αGA was dissolved in 
dimethyl sulfoxide. All chemicals were obtained from Sigma-Aldrich Sweden AB 
(Sweden). Monoclonal mouse antibodies used for HSP27 (ab8600), HSP70 (ab6535), 
HSP90 (ab1429) and nitrotyrosine (ab7048), and secondary biotinylated polyclonal 
goat anti-mouse IgG antibody (ab6788) were obtained from Abcam plc (UK, 
Cambridge).  
 
3.5 CALCULATIONS  
 
Pressure myography: Constriction to NE, AngII was calculated as a percentage change 
from initial diameter. Relaxation to flow, ACh, BK and SNP were calculated as a 
percentage change in internal diameter in response to stimulation, divided by the 
difference in internal diameter before and after pre-constriction. 
 
Wall shear stress (τ, dyn/cm2) was calculated using the Hagen-Poiseuille formula:  
τ = 4 × η × Q × 109/ πr3, 
where η is viscosity of the perfusate (poise – dyn s/cm2), Q is flow rate (µl/s) and r is 
artery radius (µm). The factor of 109 in the equation is to correct the use of µl/s for flow 
and µm for artery radius (1µl = 109 µm3). Viscosity of PSS was assumed as 0.007 poise 
at 37oC.  
 
Cross-sectional area (CSA) was calculated as:  
CSA = (π/4) × (De2 –Di2), 
where De and Di are external and internal diameters, respectively.  
 
Wall/lumen ratio was defined as:  
Wall thickness / Di. 
 
The tone developed by artery at resting condition (60 mmHg, basal tone) and pressure-
induced myogenic tone was calculated as:  
Basal tone (%) = 100 × (D60 Ca2+-free PSS – D60 PSS) / D60 Ca2+-free PSS, 
Myogenic tone (%) = 100 × (Di Ca2+-free PSS – Di PSS) / Di Ca2+-free PSS, 
where Di is the internal diameter of the artery, respectively.  
 
Distensibility index was calculated as:  
Distensibility index (%) = (Di/D0 ) × 100, 
where Di is the internal diameter in Ca2+-free PSS at different steps of pressure and D0  
is the internal diameter in Ca2+-free PSS at 5 mmHg.  
 
Wire myography: The force developed by the artery per square mm of artery wall 
during application of a certain concentration of a vasoactive substance was calculated 
using Myodata (version 2.1, Danish Myo Technology). Constriction response was 
expressed as a percentage of the maximal constriction with KPSS. The relaxation to 
agonist was calculated as a percentage of the constriction. Negative log concentration 
required to achieve 50% of the maximum response (pEC50) was calculated by nonlinear 
regression analysis (BioDataFit 1.02).  
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The homeostatic model assessment (HOMA) index was calculated as fasting insulin 
concentration (μlU/mL) × fasting glucose concentration (mmol/L)/22.5. 
 
 
3.6 STATISTICAL ANALYSIS 
 
Baseline characteristics of the patients and arteries used were analyzed by conventional 
parametric and non-parametric methods where appropriate. Analysis of variance 
(ANOVA) for repeated measures was used to compare response to stimulation before 
and after incubation with inhibitors and for differences in stimulus responses between 
the experimental groups. Student’s t-test was used to compare pEC50 value. Spearman’s 
rank correlation was used to evaluate univariate correlation. 
 
The semi-quantitative analysis for ICH staining intensity was assessed by the average 
blind score of 3 observers: using a scale between 0 and 3, where 0 was absence of 
staining and 3 corresponded to maximal intensity. In addition, a computer image 
analysis software (ImageJ), available at http://rsb.info.nih.gov/ij/index.html, was used 
for quantitative analysis of immunostaining (Rangan and Tesch, 2007; Takacs et al., 
2008). The results were evaluated with Mann-Whitney U test for non-parametric 
comparisons. Statistical analyses were performed using STATISTICA (version 7.0 and 
8.0, StatSoft, Uppsala, Sweden). All comparisons were considered statistically 
significant if P < 0.05. 
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4 RESULTS AND DISCUSSION 
 
4.1 STUDY I (ESRD) 
 
4.1.1 Clinical data 
 
Age, gender and smoking status were similar between the groups (Table 1, Paper I). 
The BMI was lower in ESRD group vs. controls.  Whereas inflammation markers 
(hsCRP and IL-6) and ADMA level were elevated in the ESRD group, total cholesterol 
was significantly lower in comparison with controls. There was no significant 
difference in blood pressure between the groups. Treatment with antihypertensive and 
lipid-lowering drugs can be explanation for the similarity in blood pressure between the 
groups, and for the lower total cholesterol level in ESRD patients compared to controls.  
 
4.1.2 Resistance artery structure and function  
 
The arteries from all groups had similar diameters, wall thickness, wall/lumen ratio and 
cross-sectional area indicating unchanged structure of resistance arteries in ESRD 
patients compared to controls (Table 2, Paper I).  
 
4.1.2.1 Endothelial function 
 
We show for the first time that flow-induced dilatation is impaired in the isolated 
resistance arteries from patients with ESRD (Figure 1A, Paper I). The presence of 
endothelial dysfunction in the resistance vasculature of ESRD subjects was further 
strengthened by a reduced dilatation in response to ACh (Figure 3A, Paper I). Current 
evidence of endothelial dysfunction in ESRD patients is primarily obtained from in vivo 
investigations on large vessels (Sahin and Yalcin et al., 2007; Verbeke and Agharazii et 
al., 2007) or measurements of circulating biomarkers (Stenvinkel et al., 2008). 
Although there was one study on the wire myography reporting reduced agonist-
induced dilatation in subcutaneous arteries (Morris and McMurray et al., 2001).  
 
We have shown the lack of NO contribution to flow-induced relaxation in ESRD 
patients (Figure 2A, Paper I). Our study suggests potential mechanisms behind small 
artery dysfunction in ESRD. Namely, the increased expression of nitrotyrosine in the 
vascular wall of arteries from ESRD patients may imply the enhancement of free 
radical production towards a pro-oxidant environment and NO degradation. On the 
other hand, the elevated circulating ADMA levels in ESRD patients might favour 
decreased NO production. Thus, reduced NO production and enhanced NO degradation 
are both involved in the altered NO availability in ESRD patients at the level of 
resistance arteries. The relative impact of each pathway to the general dysfunction, as 
well as possible alterations of other co-factors of NO synthesis, resulting in reduction of 
NO bioavailability remain unknown and deserve further investigation. 
 
Our findings of blunted  flow-induced  dilatation  and  the lack of NO contribution to 
this response in human peripheral resistance vasculature extend and complement 
previous reports,   but   in   other   vascular   beds (Annuk, 2005; Passauer and Pistrosch 
et al., 2005; Passauer and Pistrosch et al., 2005), emphasizing  further  the  general  
state  of  endothelial dysfunction  and  the  significant  role  of  impaired  NO 
availability in this group of patients with a high risk of CVD. 
 32 
 
Moreover, we suggest that impaired shear stress-induced relaxation ex vivo might be 
more aggravated in vivo due to a high prevalence of anaemia in ESRD patients. Despite 
intensive erythropoietin treatment, ESRD patients have low haemoglobin levels (Table 
1, Paper I) and, as a consequence, they experience low blood viscosity and reduced 
shear stress in comparison with healthy subjects. The evidence of abnormal shear stress 
value is suggested by in vivo studies (Samijo et al., 2002; Verbeke and Agharazii et al., 
2007). Taken together, we postulate that in ESRD, the reduced ability of shear stress to 
induce relaxation, as presented in our study, along with anaemia-related low shear 
stress value in vivo, may further impede small artery wall ‘sensitivity’ to this 
physiological stimulus.  
 
4.1.2.2 Contractile responses 
 
We hypothesized that increased myogenic and agonists-induced constrictions might be 
contributing factors to the elevated peripheral resistance in ESRD. However, we found 
that the renal failure had no effect on contractile responses to changes in intraluminal 
pressure (myogenic constriction) and several agonists (AngII, ET-1, NE and 
phenylephrine) in isolated subcutaneous arteries (Figure 4A and Table 3, Paper I). 
These findings confirm preserved contractile vascular smooth muscle function in the 
resistance arteries of patients with ESRD. We assume that combined antihypertensive 
therapy could normalize the level of myogenic tone. This suggestion is supported by 
studies on animals (Osol G, 1986; Vettoretti S, 2006). Increased peripheral resistance in 
ESRD patients could be induced by elevated local concentrations of the tested 
vasoconstrictors, rather than changes in sensitivity of the arterial wall to them.  
 
4.1.2.3 Distensibility 
 
We found alterations in the passive properties of vascular wall (reduced distensibility 
index, Figure 4B, Paper I), that strengthens a link between ESRD and increased 
vascular stiffness reported before on large arteries (Blacher J, 1999; Peralta et al., 
2009). Combining together our findings of changed distensibility and preserved arterial 
structure, we suggest that alterations in quality and/or quantity of vascular wall 
compounds might occur at the level of resistance arteries in ESRD patients.  
 
4.1.2.4 Impact of cardiovascular co-morbidities  
 
Exclusion of patients with diabetes and/or CVD had no impact on experimental 
outcomes (Figure 5, Paper I). This suggests that most likely uraemia itself, but not 
existing co-morbidities, is the main cause of endothelial dysfunction and altered passive 
properties of the resistance vasculature. Thus, our findings contribute to the elucidation 
of mechanistic links between uraemia and vascular abnormalities. 
    
 
4.2 STUDIES II-III (PREECLAMPSIA) 
 
4.2.1 Clinical data 
 
Study II. The women with PE and healthy pregnancies were age matched. Nulliparous 
women comprised 40% and 52% in the case and control groups, respectively.  Majority 
of PE women had preterm delivery with gestational age of 34 weeks (range 31–38) in 
the PE group vs. 38 weeks (range 37–40) in the control group.  
   33 
Study III. There were no differences in age between the groups. Nulliparous women 
comprised 25% and 50% in the case and control groups, respectively.  As expected, 
infant birth weight and the gestational age at delivery were significantly lower in 
women with PE (Table 1, Paper III).  
 
4.2.2 Subcutaneous arteries (Study II)   
 
In this study we failed to observe endothelial dysfunction in resistance arteries of 
women with PE. Indeed, the concentration-response curves of BK in PSS were similar 
between arteries from PE and normal pregnant women (Figure 4.1). Incubation of 
arteries with L-NAME plus Indo induced approximately 35-40% reduction in 
relaxation to BK in both groups compared to initial responses in PSS (Figure 4.1). This 
indicates that residual relaxation, which contains the main part of relaxation, is 
mediated by EDHF-type response. Since overall reduction of BK-induced relaxation 
after inhibition of NOS and COX was more pronounced in PE group vs. controls, we 
suggest that contribution of EDHF rather than NO is impaired in relaxation induced by 
BK in arteries from women with PE.  
 
 
 
Figure 4.1. Concentration-response curves for bradykinin (BK) and contribution of 
EDHF in isolated subcutaneous arteries from normal pregnant (NP) and preeclamptic 
(PE) women in physiological salt solution (PSS) and after incubation with L-NAME 
in combination with indomethacin (L-NAME+Indo). *P < 0.05, PE vs. NP. 
 
However, it should be stressed that unchanged contribution of NO to agonist-induced 
dilatation in isolated arteries could be affected by unfavorable preeclamptic conditions 
in vivo. The oxidative stress or elevated concentrations of endogenous inhibitor of 
NOS, ADMA, both of which are known to be observed in PE, might considerably 
reduce the NO bioavailability (Roggensack et al., 1999; Slaghekke et al., 2006; Poston 
et al., 2011).   
 
4.2.2.1 Mechanisms of EDHF-mediated relaxation 
 
It has been shown previously by our group that MEGJs were the major component of 
EDHF-mediated relaxation in subcutaneous resistance arteries in normal pregnancy 
(Luksha and Nisell et al., 2004). Identification of mechanisms involved in EDHF-type 
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responses in PE by incubation of arteries with inhibitors of pathways relevant to EDHF 
has revealed 1) an impairment of MEGJs pathway and 2) heterogeneity of EDHF 
contribution and its mechanisms.  
 
Since inhibition of MEGJs revealed heterogeneity in EDHF-type response in arteries 
from women with PE, we divided the PE group into two subgroups (Figure 2, Paper II). 
In the PE-1 subgroup, incubation of arteries with18-αGA reduced EDHF-type 
responses in similar way as in normal pregnancy, suggesting a main role of MEGJs 
(Figure 2A, Paper II). In the PE-2 subgroup, incubation of arteries with 18-αGA 
induced smaller but still significant reduction of EDHF-type relaxation in comparison 
with that obtained in normal pregnancy (Figure 2B, Paper II). This indicates that 
MEGJs did not play a sole role and some additional components were involved in 
EDHF-type relaxation in arteries from women in the PE-2 subgroup. Moreover, 
division into two subgroups revealed diverse overall contribution of EDHF to total BK-
induced relaxation. In the PE-1 subgroup with a predominant role of MEGJs, EDHF-
type response was impaired considerably. However, in the PE-2 subgroup the overall 
contribution of EDHF was preserved compared to controls.  
 
Thus, we speculated that one or more additional mechanisms became involved in 
EDHF-type response in the PE-2 subgroup. They could serve to compensate the 
reduced MEGJs contribution and thereby preserve overall EDHF-type relaxation in PE 
to the level similar to that in normal pregnancy. Indeed, further investigation of EDHF-
mediated mechanisms in arteries from the PE-2 subgroup supported our assumption. 
H2O2 and CYP450 metabolites of AA were responsible for EDHF-type relaxation in 
the PE-2 subgroup as supplementary or/and alternative candidates along with 
significantly reduced MEGJs component (Figure 4A and Figure 5A, Paper II).  
 
For some unknown reasons the supplementary mechanism/s to MEGJs pathway were 
not triggered in the PE-1 subgroup and as a consequence the EDHF-type response 
became reduced in comparison with both normal pregnancy and the PE-2 subgroup. At 
this stage we cannot provide an explanation of heterogeneity in overall contribution and 
diverse mechanisms of EDHF-type response in subcutaneous arteries from women with 
PE and further research is warranted. Considering a heterogeneous character of PE as a 
pregnancy-related disorder, special attention should be paid to the selection criteria 
aiming to diminish this heterogeneity through the adjustment of recruited women 
according to the severity of the disorder. Such approach in the recruitment procedure is 
of importance especially in the research focused on identification of mechanisms 
behind of abnormalities specific for PE.   
 
Implication of ultrastructural analysis of vascular wall supported our pharmacological 
evidence of MEGJs importance in subcutaneous arteries. In arteries from normal 
pregnant women, a relatively large number of long protrusions sent from ECs through 
the IEL toward SMCs were detected. ECs and SMCs formed close contacts (Figure 6, 
F–J, Paper II) previously referred to pentalaminar structures (Figueroa et al., 2004) and 
considered to serve as a prerequisite for MEGJs (Figure 6, F–H, Paper II). In contrast, 
in arteries from women with PE, we found a number of changes in morphology of the 
vascular wall. Those changes primarily included alterations in the morphology and size 
of ECs themselves (Figure 7, C and D, Paper II) accompanied by an apparent 
deficiency of  projections toward SMCs (Figure 7, B and E, Paper II). The thickness of 
IEL had also a tendency to be enhanced compared to controls. Those morphological 
alterations could cause an obstacle to the establishment of tight intercellular contacts 
between ECs and SMCs (Figure 7, Paper II). Indeed, deficiency of pentalaminar-like 
   35 
structures was observed in vessels from women with PE, resulting most likely in 
impaired communications between ECs and SMCs. 
   
Thus, heterogeneous contribution of EDHF and involvement of MEGJs, H2O2 and 
CYP450 epoxygenase metabolites of AA in the EDHF-type responses were revealed in 
subcutaneous resistance arteries in PE. Such multifaceted changes in the mechanisms 
of endothelium-dependent relaxation could indicate that peripheral resistance arteries 
are indeed affected by the unfavorable conditions associated with PE. Therefore, we 
speculate that in spite of preserved overall endothelium-dependent relaxation to BK, the 
endothelial function of peripheral resistance arteries could be vulnerable and easily 
turned to the state of endothelial dysfunction in vivo and/or later in life.  
 
4.2.3 Myometrial arteries (Study III)   
 
In contrast to subcutaneous, in myometrial arteries from women with PE the overall 
endothelium-dependent response to BK (i.e. in PSS) was significantly reduced in 
comparison with normal pregnancy (Figure 4.2). Thus, endothelial dysfunction in PE, 
defined as reduced vasodilator response to endothelium-dependent agonist, was evident 
in the isolated small arteries from the uterine but not from the peripheral (subcutaneous) 
circulation.  
 
 
 
Figure 4.2. Concentration-response curves for bradykinin (BK), time control and 
contribution of EDHF in small myometrial arteries from normal pregnant (NPG) and 
preeclamptic (PE) women in physiological salt solution (PSS) and after incubation 
with L-NAME in combination with Indomethacin (L-NAME+Indo). P < 0.05; * - PE 
vs. NPG; # - before vs. after incubation with L-NAME+Indo. Open and closed 
triangles indicate a time control experiments only with the presence of vasoconstrictor.  
 
As in subcutaneous arteries, incubation with L-NAME plus Indo resulted in significant 
reduction of BK-induced relaxation of myometrial arteries from both groups (PE and 
normal pregnancy) compared to that obtained in PSS. Moreover, the response to BK 
after incubation with L-NAME plus Indo was reduced in PE compared with normal 
pregnancy to the same extent observed in PSS (Figure 4.2). Hereby, we have concluded 
that in myometrial arteries 1) EDHF was a predominant mediator for endothelium-
dependent relaxation to BK and 2) EDHF-type, rather than NO-mediated response was 
impaired in PE.  
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To clarify the mechanisms behind the reduced contribution of EDHF to endothelium-
dependent dilatation in PE we applied diverse inhibitors of putative EDHF-mediated 
pathways by analogy with the Study II. As in subcutaneous, incubation of myometrial 
arteries from normal pregnant women with 18-αGA almost abolished the EDHF-type 
relaxation pointing out that MEGJs was a main component of EDHF-type responses of 
small arteries from both peripheral and uterine circulations (Figure 3, Paper III). Thus, 
our data are in line with previous finding for the potential role of MEGJs in EDHF-
typed responses in myometrial arteries in normal pregnant women (Kenny and Baker et 
al., 2002).  
 
In PE, pharmacological inhibition of MEGJs had no effect on EDHF-type relaxation in 
myometrial arteries (Figure 3, Paper III). This finding suggests that MEGJs pathway of 
EDHF-type relaxation was severely impaired in PE. To our knowledge, we for the first 
time showed that disturbances at the level of MEGJs could serve as an important 
contributory mechanism to endothelial dysfunction in PE in myometrial arteries. 
However, it is premature to speculate if MEGJ malfunction could play an underlying 
role in the genesis of vascular abnormalities and, eventually, clinical features of PE, 
although a potential role of Cxs, which constitute MEGJs, for blood pressure control 
has been supported by experiments in Cx43 and Cx40 knockout mice (Liao Y, 2001; de 
Wit C, 2003).  
 
To support our pharmacological findings about critical role of MEGJs in myometrial 
arteries we used the same ultrastructural analysis of the vascular wall, as in the Study II. 
Unfortunately, the analysis of TEM images was less efficient in the case of myometrial 
arteries isolated from both normal and PE pregnancies. In fact, we have rarely observed 
the contacts between ECs and SMCs, which could be referred as MEGJs. The 
discrepancy between pharmacological and morphological approaches to identify 
MEGJs in myometrial arteries has been previously reported by others (Sweeney et al., 
2006; Kenny et al., 2002). In order to explain the difficulty to visualize MEGJs in TEM 
images, it has been suggested that most likely individual gap-junctional channels rather 
than plaques of gap-junctional channels are responsible for intercellular communication  
(Figueroa and Isakson et al., 2004). Moreover, extremely limited number of MEGJs 
and too low density of the gap-junctional channels might further aggravate 
visualization of MEGJs at the TEM images (de Wit et al., 2008). 
 
Importantly, in spite of the lack of the MEGJ contribution in myometrial arteries in PE, 
the EDHF-type responses still comprised more than half of overall relaxation in 
response to BK (Figure 4.3). Thus, as in subcutaneous, in myometrial arteries from 
women with PE alternative EDHF pathways occurred. While administration of 
inhibitor of CYP2C9 epoxygenase revealed that AA metabolites did not participate in 
EDHF-mediated relaxation (Figure 5, Paper III), endogenous H2O2 had a substantial 
input into EDHF-type response (Figure 4A, Paper III).  Thereby, an alternative EDHF 
pathway occurred predominantly via H2O2 in myometrial arteries in PE. Since catalase 
did not abolish EDHF-type response completely (Figure 4A, Paper III), the 
involvement of other mechanisms in EDHF-type responses in PE, including those yet 
unknown could be suggested. 
 
Detection of H2O2 role in the control of endothelium-dependent relaxation of 
myometrial arteries in PE could partly explain the failure of the relatively recent 
“Vitamins in Preeclampsia-trial” (Poston et al., 2006). According to this trial, 
antioxidant vitamins supplementations from the second trimester of pregnancy in 
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women at increased risk for the gestational hypertension did not prevent PE, and 
increased the rate of low birth weight babies (Poston and Briley et al., 2006). 
Considering important role of H2O2 in the maintenance of vasodilator capacity of small 
myometrial arteries in PE, antioxidant therapy could possibly eliminate the dilative 
response induced by H2O2. That could lead to decrease of diameter of myometrial 
arteries with further reduction in the blood supply to the fetoplacental unit and 
eventually could affect the fetal growth. However, further research is warranted to 
understand the detailed mechanism and contribution of H2O2 to the control of resistance 
arteries’ tone in PE as well as the balance between beneficial and harmful roles of 
reactive oxidative species in the pathogenesis of PE in general. 
 
 
4.3 STUDY IV (HISTORY OF PREECLAMPSIA) 
 
4.3.1 Clinical data 
 
The baseline clinical and biochemical characteristics of the women with a history of 
severe early-onset PE and women with a history of uncomplicated pregnancies are 
summarized in Table 1 and Table 2 in the Paper IV. Women were matched for age, 
BMI, smoking status and time after delivery. HELLP syndrome, recurrent PE, IUGR, 
and small for gestational age babies were the features of previously preeclamptic 
women at index pregnancy.  
 
All women in our study were normotensive, non-obese and with normal glucose and 
lipids homeostasis. No evidence of kidney dysfunction and inflammation was detected 
in women with a history of PE. Thus, all women with a history of PE enrolled in our 
study were without known cardiovascular risk factors. However, there were significant 
differences in blood pressure, insulin level and HOMA index as well as a clear 
tendency (p=0.05) to the higher level of the waist to hip ratio in the case vs. control 
groups. Thereby, elevated levels of characteristics attributed to features of metabolic 
syndrome, found already 2 years after preeclamptic pregnancies in clinically healthy 
women suggest that these women may have a susceptibility to metabolic syndrome and 
they are likely to be predisposed for the development of hypertension and other 
cardiovascular complications later in life. Analysis of the clinical data of women at the 
first trimester of their index pregnancy, unfortunately did not give an answer if the 
features of metabolic syndrome were present before clinical manifestation of PE since 
the data were restricted (n=11) and had no measurements on lipid or precise glucose 
profile. Thus, it is still unclear if our findings of abnormalities at the level of resistance 
vasculature were induced by PE per se or they were inherent in these women and 
further unmasked when pregnancy advanced.  
 
4.3.2 Resistance artery structure and function  
 
This is the first study where structure, passive properties of vascular wall and 
endothelial and smooth muscle function of isolated resistance arteries were assessed in 
women with a history of severe early-onset PE. We found that structure of arteries was 
preserved (Table 3, Paper IV). 
 
4.3.2.1 Dilative responses  
 
Impaired endothelium-dependent dilatation to flow (Figure 1, Paper IV), but preserved 
response to BK (Figure 3, Paper IV) were found in women with a history of early-onset 
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PE. Our finding of reduced flow-induced dilatation in resistance arteries concurs with 
previous reports of the reduced response to flow in brachial artery in vivo in women 
with a history of early-onset PE (Germain et al., 2007; Hamad et al., 2007; Yinon and 
Kingdom et al., 2010). To our knowledge, we are the first who studied endothelium-
dependent dilatation in response to BK in women with a history of PE. However, 
attenuated dilatation to another endothelium-dependent agonist ACh  has been shown 
previously in the forearm blood flow and in the skin microcirculation 5-6 and 25 years 
after PE, respectively (Ramsay et al., 2003; Lampinen KH, 2006). The discrepancy 
could be attributed to different vascular beds, follow up periods or CVD risk profile. 
However, it is most likely that involvement of the specific receptors might be of 
importance, since in PE reduced endothelium-dependent responses to ACh but not to 
BK have been reported by others (Pascoal and Lindheimer et al., 1998).  
 
Approximately equal contribution of NO to flow- and BK-induced dilatation was found 
in the control group (Figure 2A, Figure 3B, Paper IV). Interestingly, in the case group 
the same pattern of NO contribution was observed only in response to BK (Figure 3B, 
Paper IV), whereas complete absence of NO involvement was found in flow-induced 
dilatation (Figure 2B, Paper IV). These findings support the specific deficiency of NO 
contribution in response to flow as the most physiological stimulus of endothelium-
dependent regulation of resistance artery function. It seems unlikely that enhanced NO 
degradation was the main reason for the lack of NO contribution to the flow-induced 
dilatation in the case group. Otherwise, equal inactivation of NO should occur 
irrespectively from the applied stimuli. Thereby, we speculate that disturbances of NO 
production may occur either via reduced sensitivity to shear stress (the same value of 
shear stress induced lower response in the case vs. control group) or impaired 
mechanism/s of eNOS activation by shear stress. It has been suggested, that the 
mechanisms of eNOS activation as well as sensitivity of eNOS to intracellular Ca2+ 
concentration might differ depending on stimulus applied (agonist or shear stress) 
(Fleming and Fisslthaler et al., 2001; Fleming, 2010). 
 
4.3.2.2 Contractile responses 
 
Our next important finding is increased myogenic tone in response to rapid increase in 
intraluminal pressure (Figure 6, Paper IV) and tendency to higher basal tone in 
resistance arteries from women experienced PE vs. controls. Since myogenic 
constriction is an important component of basal vascular tone, increased myogenic 
constriction might contribute to enhanced peripheral resistance and blood pressure. The 
tendency to the higher level of basal tone might contribute to higher blood pressure 
observed in the case group vs. control, even though all women were normotensive.  It 
has been reported that previously preeclamptic women with higher mean and diastolic 
blood pressure had enhanced total vascular resistance vs. controls (Evans et al., 2011). 
Furthermore, the increased myogenic tone in response to rapid changes in intraluminal 
pressure indicates on activation of protective mechanisms against rapid increase of 
blood pressure in women with a history of PE. Thereby, in our study women with a 
history of PE could be already exposed to more frequent spontaneous variations in 
blood pressure. Indeed, the study on animals has shown that increased myogenic tone 
in mesenteric arteries was evident during the development of hypertension but not 
when hypertension was established (Izzard et al., 1996). Also increased myogenic tone 
but preserved structure of femoral arteries were reported in normotensive animals with 
mild experimental uraemia (Savage et al., 1998). 
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To our knowledge, we are the first who showed increased contractile reactivity to NE 
in isolated arteries from women with a history of early-onset PE vs. controls (Figure 
8A, Paper IV). Thereby, we suggest that increased adrenergic receptors sensitivity 
and/or alterations in signal transduction pathways activated by adrenoreceptors 
stimulation might be responsible for enhanced contractile response to NE in resistance 
arteries from women with a history of PE. Since observed changes in adrenergic 
constriction took place in unison with alterations of myogenic constriction, it is possible 
to suggest that disturbances exist in general mechanisms of SMC constriction at the 
level of resistance arteries in women experienced PE. Indeed, NE- and pressure-
induced vasoconstrictions utilize similar cellular transduction mechanisms (Davis and 
Hill, 1999). In contrast, no difference was found in the vascular response to Ang II 
between the groups (Figure 9, Paper IV). The differences in the molecular events of 
intracellular signaling between AngII-induced vs. NE- and pressure-induced 
constrictions (Kanaide et al., 2003) might be one of the reasons responsible for this 
discrepancy in contractile responses observed in our study.  
 
4.3.2.3 Arterial distensibility 
 
We found that isolated resistance arteries from women with a history of early-onset PE 
had reduced distensibility in comparison with controls (Figure 10A, Paper IV), 
indicating on increased stiffness or reduced elasticity of the vascular wall. Our finding 
is consistent with a recent report of reduced arterial elasticity of small as well as large 
arteries in women with a history of early-onset PE (Souwer and Blaauw et al., 2011). 
Other studies conducted on large arteries have reported contradictory results i.e. 
reduced or unchanged arterial compliance in previously preeclamptic women (Elvan-
Taspinar et al., 2005; Rönnback and Lampinen et al., 2005; Spasojevic and Smith et al., 
2005; Lampinen et al., 2006; Pàez and Alfie et al., 2009; Robb and Mills et al., 2009; 
Yinon and Kingdom et al., 2010). Currently the exact mechanism/s of reduced 
distensibility of resistance arteries from women with previous PE is open to 
speculation. It is difficult to declare whether changes in the composition and/or in 
properties of extracellular matrices components (i.e. collagen and elastin) exist.  
 
4.3.2.4 Correlations  
 
Despite the fact that, there was no difference in HDL, LDL/HDL ratio, triglycerides, 
HbA1c, hsCRP and homocysteine between the groups, we found significant 
correlations between mentioned above biochemical markers with some functional 
parameters within the case group. In fact, LDL/HDL ratio correlated positively with 
myogenic tone (max myogenic tone in response to rapid increase in intraluminal 
pressure, Figure 6B, Paper IV) and resting basal tone (Figure 7A, Paper IV). Moreover, 
resting basal tone was positively correlated with triglycerides, HbA1c, hsCRP and 
negatively correlated with HDL (Figure 7B-E, Paper IV). Finally, the negative 
correlation was found between homocysteine levels and distensibility (Figure 10B, 
Paper IV).  At this stage it is premature to speculate whether cause-effect relationships 
exist within detected correlations. Based on our findings we can hypothesize that any 
subtle changes in the mentioned above biochemical parameters will be accompanied by 
worsening of certain functional properties. As a consequence, such events will lead to 
increase of peripheral resistance and progress to hypertension.   
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5 CONCLUSIONS: 
 
The main findings presented in this thesis substantiate the functional alterations of 
resistance arteries in subjects with increased risk of CVD.  
 
The principal conclusions are: 
 
Study I:   In patients with end-stage renal disease: 
 
• The endothelium-dependent flow- and ACh-induced dilatations are impaired.   
• The lack of NO contribution to flow-induced dilatation together with enhanced 
circulating levels of ADMA and enhanced nitrotyrosine staining in the vascular 
wall support the critical role of NO deficiency. 
• Distensibility index is reduced, indicating on increased arterial stiffness.  
• Observed alterations seem to be induced by renal failure per se rather than by 
CVD and/or diabetes mellitus.     
 
Studies II-III:    In pregnant women with preeclampsia: 
 
• Reduced endothelium-dependent  dilatation to BK is specific for myometrial 
arteries. This could contribute to the reduced uteroplacental blood flow. 
• EDHF-type rather than NO-mediated responses are impaired in both 
myometrial and subcutaneous arteries.  
• The contribution of MEGJs is reduced in subcutaneous and severely impaired 
in myometrial arteries.  
• In subcutaneous arteries the contribution and mechanisms of EDHF-type 
relaxation are heterogeneous; MEGJs alone or in combination with either 
H2O2 or metabolites of AA comprise EDHF-type response.  
• In myometrial arteries, the attenuated role of MEGJs is partly compensated 
through the contribution of H2O2 or other endothelium-derived factors. 
 
Study IV:    In women with a history of early-onset preeclampsia:  
 
• Endothelium-dependent response to flow is impaired most due to the lack of 
NO contribution.  
• Pressure-induced constriction is increased, indicating activation of myogenic 
regulation of vascular tone.  
• Sensitivity to adrenergic receptors agonist NE is increased. 
• Distensibility index is reduced, indicating on increased arterial stiffness.  
• Although the blood pressure, insulin level and HOMA index are within the 
normal range, they are higher than in women with a history of uncomplicated 
pregnancies. 
• A complex of functional alterations of resistance arteries, their correlations 
with some biochemical markers and changes in baseline clinical and 
biochemical characteristics emphasize the cardiovascular vulnerability of 
these women.  Regular medical follow ups and promotion of healthy lifestyle 
are highly recommended. 
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